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Abstract 
Diabetic retinopathy is one of the leading causes of blindness in diabetic patients. Müller cells 
are the primary glial cells of the retina and they are pivotal for the normal functioning of the 
retina. Histamine is involved in the blood-retinal barrier (BRB) breakdown that is associated 
with the pathogenesis of diabetic retinopathy, and recent evidence has specifically implicated 
an important role of histamine H4 receptor in vascular permeability. Photobiomodulation 
(PBM) refers to low-intensity infra-red light therapy which has shown promise in 
retinopathies. We have demonstrated, for the first time, the presence of the histamine H4 
receptor on murine Müller cells, particularly on the end feet of these cells. The principle aims 
of this investigation were to confirm the presence and characterize the Histamine H4 receptor 
on human Müller cells and to determine whether H4 receptor antagonists or PBM near 
infrared (NIR) wavelength 1068 nm has any therapeutic potential against diabetic retinopathy. 
Immunofluorescence (IF) analysis showed the presence of Histamine H4 receptor in the 
human Müller cells of the retina (Mio-1 cells), and this expression was upregulated in a high 
(4500 mg/L), versus low (3151 mg/L), glucose environment. IF analysis has also hinted at the 
presence of a modest nascent histamine pool in the retina through the presence of Histidine 
decarboxylase (HDC). Further pharmacological characterization of the receptor included the 
release of calcium from intracellular pools upon receptor activation with selective H4 receptor 
agonists, VUF8430 and ST-1006 of concentrations ranging from 10 nM – 100 µM. On testing 
the protective properties of H4 receptor agonist, VUF8430 (10 µM) and antagonist, 
JNJ7777120 (10 µM) against H2O2 induced (400 µM) oxidative and glyoxal-induced (2 mM) 
inflammatory damage in human Müller cells, they both showed no significant protection. 
However, pilot data showed that VUF8430 exacerbated an inflammatory response. Single 
PBM treatment at 10 mW/sq cm2 power density against oxidative stress showed modest 
protection, but double PBM treatment of the cells both pre- and post-oxidative stress 
displayed complete glioprotection, and an anti-inflammatory effect upon TNF-alpha 
gliosecretion. In conclusion, this is the first demonstration that histamine H4 receptors are 
functionally expressed on human Müller cells, which indicates the therapeutic potential of 
neutral H4 receptor antagonists in diabetic retinopathy. The study also provides evidence for 
a new non-invasive therapeutic approach (antioxidant and anti-inflammatory) for diabetic 
retinopathy based on a PBM NIR1068 nm protocol. 
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Chapter 1 
Introduction 
 
1.1 Diabetes  
 
Diabetes is a group of metabolic diseases that affects and induces long term damage 
to organs such as eyes, heart, kidneys, blood vessels and nerves due to defects in 
insulin secretion and insulin action (figure 1). Diabetes is characterised by 
hyperglycaemia, which is defined as having high blood glucose levels in the blood 
(higher than 1.26 g/l).  
 
Figure 1: Schematic diagram of the consequences of diabetes. Figure shows various 
complications in many parts of the body that can be caused by diabetes. 
 
Page | 12 
 
Diabetes falls into two categories: Type 1, which is characterised by insulin producing 
beta cell destruction in the pancreas and type 2, the most common form of diabetes, 
is characterised by both abnormalities in insulin action and secretion (Alberti and 
Zimmet, 1998). 
Diabetic patients have abnormalities in metabolism of protein, carbohydrate and fat 
because of the defective functioning of insulin. Insulin may not function properly if 
there is lack of insulin secretion or if tissues become less responsive to insulin, and 
this problem can coexist in most patients. Some symptoms of acute hyperglycaemia 
include weight loss, polyuria, polyphagia, polydipsia and blurred vision. Other 
symptoms can include susceptibility to infections and growth impairment. Severe 
symptoms due to long term hyperglycaemia include retinopathy (leads to vision 
loss), peripheral neuropathy (increased risk of amputations, foot ulcers and Charcot 
joints), autonomic neuropathy (increased incidence of cardiovascular and peripheral 
arterial disease) and nephropathy (leads to renal failure) (Diagnosis and 
Classification of Diabetes Mellitus, 2010). 
The global prevalence of diabetes was at 8.3% in 2014 and this is estimated to 
increase by 55% in 2030 (Shaw et al., 2014); thus, posing significant burden for 
healthcare costs worldwide. Diabetic patients have a high risk of developing long-
term complications like cardiovascular and microvascular diseases and current 
antidiabetic drugs are only effective in reducing the risk of acute complications but 
are not effective in reversing its progression (Murphy, 1998). Therefore, a better 
understanding of the underlying mechanism of this disease is needed for more 
effective treatments. 
1.2 Diabetic Retinopathy 
According to World Health Organization (WHO), diabetic complications can be 
divided into two broad categories, macrovascular complications and microvascular 
complications. Macrovascular complications include stroke, peripheral arterial 
disease and coronary artery disease. Microvascular complications include diabetic 
retinopathy, neuropathy and nephropathy. 
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Of the millions of people with diabetes, about a third of them have diabetic 
retinopathy, from which a third of them are at risk of loss of vision due to severe 
retinopathy called macular oedema (Saaddine, 2008). Diabetic retinopathy is also 
the most common cause of preventable blindness in working-age adults (Mohamed, 
Gillies and Wong, 2007). Even though developing countries have a low prevalence of 
diabetic retinopathy (Raman et al., 2009), this will change due to increasing 
population numbers and longer lifespans for people with diabetes around the world 
(figure 2).  
Symptoms of diabetic retinopathy can be divided into non-proliferative and 
proliferative. Non-proliferative diabetic retinopathy is defined by haemorrhages, 
microaneurysms, venous abnormalities and hard exudates. Proliferative retinopathy 
is characterized by pre-retinal or vitreous haemorrhages, neovascularization and 
fibrovascular proliferation (Cheung, Mitchell and Wong, 2010) (figure 3). All these 
can eventually lead to retinal detachment, glaucoma and vision loss (Cai and 
McGinnis, 2016). 
 
Figure 2: The global prevalence of people with diabetes and diabetic retinopathy. Chart 
highlighting the increased prevalence of diabetes and diabetic retinopathy (DR) due to 
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increasing population and lifespan. Source: http://atlas.iapb.org/vision-trends/diabetic-
retinopathy/ (Accessed on 11th February 2019) 
 
 
Figure 3. Signs of non-proliferative diabetic retinopathy. Some clinical features of diabetic 
retinopathy include microaneurysms, hard exudates and hemorrhages (A and B) (Cheung, 
Mitchell and Wong, 2010). 
 
1.2.1 Molecular mechanisms of diabetic retinopathy 
Our knowledge of the underlying molecular mechanisms for the development of 
diabetic retinopathy is still evolving. What we know so far is that chronic exposure 
to hyperglycemia and other causal risk factors leads to a cascade of biochemical and 
physiological changes that ultimately causes retinal dysfunction and microvascular 
damage. The biochemical changes proposed include effects on growth factors, 
signaling and cellular metabolism (reviewed by Cheung, Mitchell and Wong, 2010). 
Some of these pathways include accumulation of advanced glycation end-products 
(AGE), protein kinase C activation, oxidative stress, inflammation and upregulation 
of vascular endothelial growth factor (VEGF) and renin-angiotensin system. Growing 
evidence points to a prominent role of inflammation in the pathogenesis of diabetic 
retinopathy (Antonetti et al., 2006), (Xu, Chen and Forrester, 2009). A vast array of 
inflammatory mediators is upregulated in response to hyperglycemia and other 
stresses, which then triggers para inflammatory responses that causes abnormal 
leucocyte-endothelial interactions, and eventually leads to retinal microvascular 
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damage. Results from new experimental studies suggest that diabetes affects the 
entire neurosensory retina through altered metabolism of neuro-retinal supporting 
cells and accelerated neuronal activation and apoptosis (Antonetti et al., 2006). 
Understanding of this effect of diabetes on the neural retina can potentially lead to 
new treatments through neuroprotective agents. 
1.2.2 Current treatments 
Current guidelines for eye care in diabetic patients include blood pressure control 
and tight glycemic control, along with laser therapy when needed (Mohamed, Gillies 
and Wong, 2007). Several new therapies are coming up based on our understanding 
of the underlying molecular mechanisms of diabetic retinopathy. One of these is the 
drug ruboxistaurin, which is a selective protein kinase C inhibitor. Protein kinase C is 
activated by hyperglycemia, which in turn increases retinal neovascularization and 
vascular permeability. Thus, inhibition of protein kinase C can lead to reduced risk of 
progression of macular oedema (Schwartz, Flynn and Aiello, 2009). Another drug, 
pimagedine, an aminoguanidine, inhibits the formation of AGE in the retina (Bolton 
et al., 2004). The accumulation of AGE in the retina increases due to hyperglycemia 
and the level of AGE is correlated to retinopathy progression. Another drug includes 
rosiglitazone, which is an insulin-sensitising agent, can delay onset of proliferative 
retinopathy in type-2 diabetes (Genuth et al., 2005). Another therapeutic target for 
diabetic retinopathy includes VEGF inhibitors. VEGF is a potent mediator for 
abnormal retinal vessel growth and leakage (Wirostko, Wong and Simo, 2008) and 
has also been shown to be correlated to hypoxia and active neovascularization 
(Aiello et al., 1994). 
Laser photocoagulation is still the main ophthalmic therapy for vision threatening 
diabetic retinopathy due to its effectiveness in prevention of vision loss, but this 
treatment method is still destructive and can lead to significant ocular side-effects. 
Surgical treatments available for retinopathy include vitrectomy, which is effective 
against persistent vitreous hemorrhage and tractional retinal detachment, but it 
increases the risk of cataract formation and neovascularization (reviewed by Cheung, 
Mitchell and Wong, 2010). There is an urgent need for new therapeutic strategies 
that prevents and reverses ocular oedema without tissue destruction. Treatments 
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that target several pathways underlying retinal oedema and neovascularization has 
shown the most potential so far going forward.  
1.3 The retina 
The retina lies at the back of the eye and is approximately 0.5 mm thick. A simplistic 
model of the retina is composed of sensory photoreceptors and ganglion cells 
connected by few interneurons packed in the central part of the retina (figure 4).  
 
Figure 4: Simple anatomical structure of the retina (adapted from Kolb, Fernandez and 
Nelson, 1995). 
Vertebrate retinas contain three layers of nerve cell bodies and two layers of 
synapses. The nerve cell layers are composed of outer nuclear layer (ONL), 
containing cell bodies of rods and cones, and the inner nuclear layer (INL), which 
contains cell bodies of amacrine, bipolar and horizontal cells, and finally the ganglion 
cell layer, consisting of cell bodies of ganglion cells and displaced amacrine cells. 
These three nerve cell layers are divided by two neurophils where synaptic contact 
occurs. The outer plexiform layer (OPL) is where connections between rods and 
cones, bipolar cells and horizontal cells occur. Inner plexiform layer (IPL) acts as a 
relay station for bipolar cells and ganglion cells. The outer limiting membrane (OLM) 
is composed of adherens junctions between Müller cells and photoreceptor cell 
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inner segments, which forms a barrier between the subretinal space and the inner 
and outer segments of the photoreceptors project into this subretinal space to be in 
close contact with the pigment epithelial layer. Inner limiting membrane (ILM) is 
made up of Müller cell endfeet and associated basement membrane constituents 
and it lies at the inner surface of the retina bordering the vitreous humor, thus 
forming a diffusion barrier between vitreous humor and neural retina. 
The retina is supplied through capillaries running through all parts of the retina, and 
the delicate photoreceptor layer is nourished by choriocapillaris found behind the 
pigment epithelium layer.  
Since the retina is a delicate organisation of glia, neurons and blood vessels, in most 
eye diseases, the retina gets damaged or compromised (figure 5), and eventually 
leads to serious damages to the nerve cells carrying vital signals to the brain, and 
thus causing blindness. 
 
Figure 5: Damaging effects in the retina during the course of diabetic retinopathy. Diagram 
illustrates the glial cells in the retina that are affected by diabetic retinopathy and the 
adverse effects that are associated with damage to each of these cells. Müller cells play an 
important role in diabetic retinopathy as damage to these cells caused the most adverse 
symptoms associated with the disease. 
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1.3.1 Müller cells  
Müller cells are one of the primary glial cell types found in the retina, and since they 
are the only cells that span the entire width of the retina and have contact with both 
retinal blood vessels and retinal neurons, they are uniquely positioned to perform a 
variety of functions to maintain retinal function and homeostasis.  
Müller cells have three important functions in the healthy retina: 
1 Uptake and recycling of neurotransmitters, retinoic acids, and ions 
Because of the extensive contact of Müller cells with retinal neurons, they can 
actively participate in neurotransmission. They do this by rapidly taking up and 
clearing glutamate and gamma-aminobutyric acid (GABA) in the inner plexiform 
layer (IPL) (Barbour, Brew, & Attwell, 1988; Biedermann, Bringmann, & Reichenbach, 
2002; Derouiche & Rauen, 1995). The extracellular glutamate is taken up the 
Glutamate Aspartate Transporter (GLAST) and its removal through conversion by 
glutamine synthetase into glutamine, prevents neurotoxicity in the retina and 
provides substrate for neurotransmitter synthesis in the neurons (Harada et al., 
1998; Rauen, Taylor, Kuhlbrodt, & Wiessner, 1998). 
Through a process called ‘’potassium spatial buffering’’, Müller cells normalize and 
redistribute K+ in the surrounding environment to prevent prolonged accumulation 
of K+ (Orkand, Nicholls, and Kuffler, 1966). They do this by taking up K+ from the inner 
and outer plexiform layers through Kir2.1 potassium channels and releasing the K+ 
into vitreous humor through Kir4.1 channels in the Müller cell processes (Bringmann, 
Reichenbach, & Wiedemann, 2004; Nagelhus et al., 1999). 
Finally, Müller  cells participate in the retinoid cycle through cone photoreceptors by 
taking up all-trans retinol from the subretinal space, converted to 11-cis retinol by 
all-trans retinol isomerase, and released into the extracellular space to be taken up 
by the cone photoreceptors to restart the visual cycle (Edwards, Adler, Dev, & 
Claycomb, 1992; Kanan et al., 2008). 
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2 Supply of nutrients and control of metabolism in the retina 
Müller cells primarily produce ATP through glycolysis rather than oxidative 
phosphorylation (Winkler, Arnold, Brassell, & Puro, 2000) so that other cell types and 
retinal neurons can use oxygen through oxidative phosphorylation to produce ATP. 
Müller cells are also the primary site of glycogen storage in the retina (Kuwabara & 
Cogan, 1961; Winkler et al., 2000), which means that they can provide metabolites 
to other cells when nutrient supplies are low. Furthermore, the lactate that Müller 
cells produce through glycolysis can be transported to photoreceptors in case of 
need to be used as an alternative source of energy (Poitry-Yamate, Poitry, & 
Tsacopoulos, 1995; Winkler et al., 2000).  
3 Regulation of blood flow and maintenance of blood retinal barrier 
In terms of a healthy retina, one of the most important functions of Müller cells is 
their ability to regulate retinal blood flow and maintain the integrity of the blood 
retinal barrier, to prevent leakage of blood and pathogens from entering the retinal 
tissue. Evidence of this role of Müller cells includes the study where conditional 
ablation of the cells resulted in severe blood retinal barrier breakdown (Shen et al., 
2012). The mechanism of contribution of Müller cells to the blood retinal barrier 
includes secretion of pigment epithelium-derived factor (PEDF) and 
thrombospondin-1, which increase the tightness of the endothelial barrier due to 
their anti-angiogenic properties (Bringmann et al., 2006); though this mechanism is 
still highly debated.  
1.4.1 Müller cells in disease 
Since Müller cells have intricate contact with other cell types in the retina, it is easy 
to see why any disturbances to these cells can affect function, viability and cross-talk 
in neurons. As stated above, Müller cell ablation in an experiment resulted in 
vascular leakage, photoreceptor degeneration and intraretinal neovascularization, 
which suggests that these cells are important for neuronal and vascular function 
(Shen et al., 2012, 2014). When Müller cell environment is changed through 
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hyperglycemia, it was observed that functional interaction with pericytes was 
altered in these cells (Muto et al., 2014). It was suggested that the breakdown of the 
blood retinal barrier is caused by improper localization of the dystrophin-Dp71 
protein as deletion of the protein causes the protein to localize in the endfeet of 
Müller cells, thus causing extensive vascular leakage and edema in the mouse retina 
(Vacca et al., 2016). 
1.4 Histamine  
Histamine [2-(4-imidazolyl)-ethylamine] is an endogenous autacoid that is found in 
high concentrations in vertebrate tissues like skin, lungs and gastrointestinal tract. It 
is synthesized from L-histidine through catalytic activity of histidine decarboxylase 
(HDC) (Bodmer, 1999) (figure 6).  
 
Figure 6: Chemical reaction showing the formation of Histamine from L-histidine through 
catalytic activity of HDC.  
Histamine is responsible for a range of physiological processes such as dilation of 
capillaries, smooth muscle contraction, gastric acid secretion, inflammation and 
neurotransmission. This autacoid acts through binding to four distinct G-protein 
coupled receptors (GPCR), H1R, H2R, H3R and H4R, in chronological order of 
discovery. Homology between the receptors is very low, except H3 and H4 receptors 
(Leurs et al., 2012). A common feature in all four receptors is the negatively charged 
aspartate residue in transmembrane 3, which is the binding site for the amine 
function of histamine. Histamine is most commonly found in cytostolic granules in 
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basophils and mast cells and released in response to immunological and non-
immunological responses through exocytosis (Kakavas S, 2006). 
 
1.4.1 Histamine H1 receptor 
The H1 receptor is expressed on various cell types, such as hepatocytes, endothelial 
cells, chondrocytes, nerve cells (Lo, 1987), dendritic cells (Ohtani, 2003) and 
neutrophils (Taniguchi, 1991). The receptor is linked to Gq/11 protein, and on 
activation of the receptor, the Gq/11 protein activates phospholipase C (PLC), which 
then catalyzes the hydrolysis of phosphatidyl-4,5-bisphosphate (IP2) into inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). When the role of histamine was 
discovered in allergic reactions, the first anti-histamines targeted the H1 receptor by 
antagonizing the effects of histamine on the receptor (Hill et al., 1997, Simons and 
Simons, 2011). 
1.4.2 Histamine H2 receptor 
The histamine H2 receptor was first discovered to modulate smooth muscle and 
gastric acid secretion in the periphery (Hill et al., 1997). In terms of its mechanism of 
action, it is constitutively active, and upon activation, it activates adenylyl cyclase 
through Gs-proteins (Dy and Schneider, 2004). 
1.4.3 Histamine H3 receptor 
Histamine H3 receptor was first found as a pre-synaptic auto-receptor on 
histaminergic neurons in the brain (Arrang et al., 1983), but we know that it is 
present on both histaminergic and non-histaminergic neurons. H3 receptor is mostly 
expressed in central nervous system (CNS) tissues, but it is also detected in the 
periphery such as mast cells and the gut (Imamura, 1995, Coruzzi, 2010). The 
receptor is constitutively active, and it acts through linked Gi/o proteins (Morisset, 
2000). On activation, H3 receptor can inhibit the release of histamine and other 
neurotransmitters such as dopamine, glutamate, serotonin, noradrenalin, 
norepinephrine and γ-amino butyric acid (GABA) (Leurs, 1998). H3 receptor is 
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different from H1 and H2 receptors pharmacologically as activation of the receptor 
inhibits cAMP production through adenylyl cyclase. 
H3 receptor is known for its critical role in homeostatic regulatory functions such as 
food intake and bodyweight (Hancock et. al, 2005). Recently, this receptor has been 
shown to be present in pancreatic alpha and beta cells, and activation of the receptor 
with Imetit inhibits insulin secretion in MIN6 cells (Nakamura et. al, 2014); thus, 
showing a potential diabeto-genic effect of H3 receptor in the pancreas.  
1.4.4 Histamine H4 receptor 
H4 receptor is mostly expressed on cells from the haematopoietic lineage e.g. T-cells, 
basophils, mast cells, eosinophils and dendritic cells (van Rijn et al., 2008, Dijkstra et 
al., 2007, Dijkstra et al., 2008, Oda T., 2001). Apart from cells of haematopoietic 
lineage, H4 receptors have also been found on neurons of dorsal root ganglia, lamina 
I and II of the lumbar spinal cord (Lethbridge and Chazot, 2010b, Connelly et al., 
2009, Strakhova et al., 2009) and on nerves of human nasal mucosa (Nakayama et 
al., 2004). 
1.4.4.1  Biochemistry 
Once H4 receptor is activated, its Gα and Gβγ subunits dissociate from the receptor, 
and the Gβγ subunits activate phospholipase C (PLC), resulting in the production of 
diacyglycerol (DAG) and inositol-1, 4, 5, -triphosphate (InsP3). InsP3 further releases 
calcium stored in intracellular calcium vesicle stores. The Gα subunit once activated, 
negatively regulates the activity of adenylyl cyclase (AC), which is responsible for the 
formation of cAMP from ATP. cAMP is involved in activating protein kinase A (PKA), 
which then phosphorylates cAMP responsive element-binding protein (CREB). The 
reduction in PKA activity results in increase in mitogen activated protein kinase 
(MAPK) activity (Van Rijn, 2006). This mechanism of H4 receptor signaling is shown 
in figure 7. Activation of H4 receptor also inhibits forskolin induced cyclic adenosine 
monophosphate (cAMP) production (Lovenberg, 1999). Interestingly, it has also 
been shown that H4 receptor exhibits constitutive activity, as illustrated by increased 
basal level of MAP kinase phosphorylation and [35S] GTPγS binding in H4 receptor 
expressing cells (Morse et al., 2001). 
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Figure 7: An overview of H4 receptor signal transduction (Iwan, 2005). On H4 receptor 
activation, both Gα and Gβγ subunits take part in intracellular signaling. Gβγ subunit 
activation leads to production of DAG and InsP3. InsP3 further releases calcium stored in 
intracellular calcium vesicle stores. The Gα subunit once activated, negatively regulates the 
activity of adenylyl cyclase (AC), which results in decreased levels of cAMP and subsequent 
downregulation of the transcription factor CREB. This in turn results in increase in mitogen 
activated protein kinase (MAPK) activity. 
 
1.4.4.2  Agonists 
Early pharmacological studies of the H4 receptor was carried out using ligands 
designed for the homologous H3 receptor as there was a lack of specific H4 ligands. 
OUP-16 (figure 8A) was the first ligand selective for H4 receptor, with a 40-fold 
selectivity over the H3 receptor (Hashimoto et al., 2003). 4-methylhistamine (figure 
8B) is another ligand with high affinity for the H4 receptor and displays a 100-fold 
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selectivity over the other histamine receptors (Lim et al., 2005). Another important 
agonist is VUF 8430 (figure 8C), which has full agonistic activity and a 30-fold 
selectivity over the H3 receptor (Lim et al., 2009). 4-methylhistamine and VUF 8430 
together can be used as powerful tools to study H4 receptor pharmacology. Another 
agonist utilized in this study includes the aminopyrimidine ligand ST-1006, which is a 
partial H4 receptor ligand (Panula et al., 2015). 
 
 
Figure 8: H4 receptor agonists. 
1.4.4.3  Antagonists 
The first H4 receptor antagonists used to characterize the receptor were imidazole-
containing dual H3 and H4 receptor compounds (Gbahou et al., 2006) such as 
thioperamide (figure 9A), which is a H3 antagonist and H4 receptor inverse antagonist 
(Buckland et al., 2003, Hofstra et al., 2003). The most important human H4 receptor 
antagonist so far is JNJ 7777120 (figure 9B), as it has high affinity for H4 receptor (Ki, 
4 nM) and 1000-fold selectivity over the other receptors (Fung-Leung et al., 2004). 
This H4 antagonist has been used extensively to elucidate the role of H4 receptor in 
various inflammatory and allergic processes (Coruzzi et al., 2012), and its anti-
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inflammatory properties suggests that H4 receptor antagonists can possibly be used 
as anti-inflammatory drugs. 
 
Figure 9: H4 receptor antagonists. 
1.4.5 Role of Histamine in diabetes 
A lot of current evidence points to a significant role of histamine in diabetes. The first 
evidence for the role of histamine in diabetes came from the work of Gill and 
colleagues who showed that there is an increase in histamine content in plasma and 
leucocyte of patients with diabetes which they concluded resulted in pathogenesis 
of increased endothelial permeability in diabetic patients (Gill et al., 1989). Other 
evidence includes the activation of mast cells by advanced glycation end-products 
(AGEs), which results in release of histamine from mast cells and as a result causes 
the low-grade inflammation which is typical of diabetes (Sick et al., 2010). Work in 
rodents has also contributed considerable evidence; this includes increased 
histamine level in the kidney, lung, brain, plasma, heart, intestine and pancreas of 
diabetic rats (Fogel et al., 1990) and when insulin is administered to these rats, it was 
reported to lower histamine production in plasma and aorta (Orlidge and Hollis, 
1982, Hollis et al., 1985).  
Further evidence of this include the report of an increase in pancreatic islet 
histamine content streptozotocin (STZ)-induced diabetic rats (Azevedo et al., 1990). 
Due to its well-known vascular actions, histamine has been suggested to be a key 
triggering stimulus for microvascular diseases of diabetes, such as diabetic 
retinopathy (El-Asrar et al., 2004). The role of histamine in this microvascular disease 
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has been implicated using antihistamines, such as astemizole, diphenhydramine and 
ranitidine, which have been shown to reduce leakage of retinal vessels in diabetic 
rats and human (Hollis et al., 1992, Gardner et al., 1995) and also reduce 
permeability of blood-brain barrier (Patnaik et al., 2000). Thus, these data suggest 
that histamine plays a role in the neural cell contribution in diabetes-induced 
vascular leakage. 
The observation that there is reduced hyperglycemia in HDC-/- NOD mice (Alkan et 
al., 2015), which is the animal model for spontaneous type 1 diabetes, suggests that 
there is nascent histamine pool in various tissues. This is backed up by the 
observation that there is a simultaneous reduction in intestinal diamine oxidase 
(DAO) activity and increase in histidine decarboxylase (HDC) activity in tissues (Gill, 
Thompson and Dandona, 1990).  
In terms of the role of histamine in diabetic retinopathy, it has been reported that 
there is reduced zonula occludens (ZO)-1 expression in cultured retinal microvascular 
endothelial cells in the presence of histamine (Gardner et al., 1996) and the same 
effect is observed in the presence of high glucose and low insulin (Gardner et al., 
1995). These data suggest that histamine induces BRB (blood-retina barrier) 
dysfunction in diabetes and consequently vascular leakage, which contributes to the 
pathogenesis in diabetic retinopathy. Interestingly, these effects are similar to those 
observed for VEGF on permeability leakage (Leal et al., 2005). More evidence that 
points to a direct role of histamine in diabetic retinopathy is the study where an 
increase in histamine synthesis was observed in the retinas of diabetic rats (Hollis et 
al., 1992, Carroll et al., 1988) due to an over-expression of HDC in retinal neurons 
and glia (Gastinger et al., 2001) and the histamine overproduction was reduced when 
HDC or insulin was administered (Carroll et al., 1988). This is important because of 
the current acknowledgment that in diabetic retinopathy, molecular, cellular and 
functional changes occur in all the retinal cellular compartments (Barber et al., 1998, 
Abu-El-Asrar et al., 2004). 
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1.4.6 Importance of H3 and H4 receptors in Diabetes 
The histamine receptors that will be the focus of this study will be H3 receptor and 
H4 receptor. H3 receptor is primarily located in the CNS, where it acts as both an auto- 
and hetero-receptor to control the release of histamine and other 
neurotransmitters. Apart from CNS, H3 receptor has also been found in sensory 
neurons and dorsal root ganglia (Cannon et al., 2007). Like H3 receptor, H4 receptor 
is also found in human CNS (Coge et al., 2001), but recently it has been found to be 
also expressed in endothelial cells, which indicates its potential role in vascular 
permeability (Karlstedt et al., 2013). It is well known that there are different isoforms 
of histamine receptors, and our group has shown that three of the common H3 
receptor isoforms (hH3 329, hH3 365, hH3 445) are expressed in the human brain 
(Lethbridge, 2011). This is important as human H3 receptor homomeric isoforms and 
heteromeric subtypes display differential pharmacological properties. 
Recent data also points to the involvement of peripheral H3 receptor in the insulin-
histamine loop (Pini et al., 2015). The presence of functional H3 receptor was also 
reported in diabetic pancreas, showing the involvement of H3 receptor in diabetes 
for the first time, where the authors showed that the activation of the receptor with 
Imetit inhibits insulin secretion in a high glucose environment (Nakamura et al., 
2014). So far, this has been tested by a synthesized H3 receptor antagonist in diabetic 
animal models, where the drug was effective in reducing non-fasting glucose levels 
by blocking the increase of HbA1 (Large-scale association analysis provides insights 
into the genetic architecture and pathophysiology of type 2 diabetes, 2012). On the 
contrary, it’s reported that the activation of H3 receptors in DiO mice increases 
energy expenditure and decreases food intake, while chronic exposure of the mice 
to H3 receptor agonist reduces fat mass, body weight, hyperinsulinemia and 
hyperleptinemia. In contrast, it was observed that the H3 receptor agonist Proxyfan 
improves glucose exclusion in mice, increasing their plasma insulin levels without 
any changes in plasma glucagon levels (Henry et al., 2011). In addition to this, H3 
receptor deficient mice, which are mildly obese, demonstrate insulin and leptin 
resistance along with defective glucose tolerance (Yoshimoto et al., 2006). In the 
kidney, it’s also shown there is a profound increase in H3 receptor and H4 receptor 
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expression in diabetic animals (Pini et al., 2015, Rosa et al., 2013). These studies raise 
the possibility of contradictory effects mediated by central and peripheral H3 
receptor. These contradictory observations could also be attributed to the different 
animal models used, the variance in doses, selectivity of the compounds and the 
administration route, which could all differentially affect the peripheral and central 
histaminergic system (Pini et al., 2018). 
1.5 Photobiomodulation  
Electromagnetic (EM) waves are photons of light that vibrate at different rates. They 
display both magnetic and electrical properties and due to the different vibration 
rates of the photons, EM waves have different wavelengths and photon energy 
(Enwemeka, 2004). The EM spectrum consists of infrared (IR) radiation, ultraviolet 
rays, gamma rays, x-rays, radio waves and cosmic rays (figure 10). Due to the varying 
energy of the photons, different wavelengths of the spectrum have varying effects 
in cells. For example, at the lower end of the spectrum, with shorter wavelengths 
and higher energy, gamma rays, x-rays and UV rays can produce damaging effects in 
cells. Whereas at the other end of the spectrum, lower energy and longer 
wavelengths like radio waves are harmless to cells. Visible light and near-IR fall 
between the two extremes and these wavelengths have been shown to have 
therapeutic effects in cells. 
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Figure 10: The electromagnetic spectrum. Figure illustrating the different wavelength of the 
electromagnetic spectrum and the subcategories that infrared light is split into. 
1.5.1 Use of IR and near-IR light as a therapeutic tool 
The use of lasers in a clinical setting is impractical for various reasons: limitations in 
altering wavelengths, bulky equipment and excessive hardware and the risk of 
damage to tissues and the retina from the laser light (Whelan et al., 2001; Eells et 
al., 2004; Brawn and Kwong-Hing, 2007). Light Emitting Diodes (LED) have become a 
suitable alternative to lasers as they can produce varying wavelengths, have less 
cumbersome hardware and have reduced risk of tissue and eye damage due to lower 
production of heat compared to lasers (Whelan et al., 2001; Eells et al., 2004; Brawn 
and Kwong-Hing, 2007). On top of this, experimental evidence at the cellular level 
has shown that Laser and LED at the same wavelength, irradiation time and intensity 
have similar biological effects. (Karu, 2003). 
Photobiomodulation (PBM) refers to the use of red or near-infrared light (630-1100 
nm) to heal, stimulate and protect tissues which are injured or is at risk of dying. 
PBM was accidentally discovered by Endre Mester in 1967, when while repeating an 
experiment, he used a low-powered laser to destroy a cancerous tumor implanted 
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onto a rat. He noticed that instead of destroying the tumor, the light had caused the 
wounded skin of the heat to heal quicker compared to the control rats. He followed 
up this observation with further experiments on burns, skin defects, ulcers, wounds 
and bedsores (Enwemeka, 2004). 
A common effect observed with PBM is increased cellular proliferation. This effect 
has been observed at different wavelengths for various cell types like fibroblasts 
(Vinck et al., 2003), osteoblast cells (Kreisler et al., 2003a; Ueda and Shimizu, 2003; 
Pires Oliveira et al., 2008), olfactory ensheathing cells (Byrnes et al., 2005b), human 
larynx carcinoma cells (Kreisler et al., 2003b) and rabbit aortic endothelial cells (Ricci 
et al., 2009). Thus, from these observations, it can be inferred that tissue repair seen 
with PBM treatment may be due to increased cellular proliferation.  
In animal models, PBM has been shown to reduce oxidative stress associated with 
diabetes (Henshel et al., 2009, Tsai et al., 2001). In in-vitro models, treatment of 
visual cortical neurons with 670 nm NIR light before exposing the neurons to 
potassium cyanide reduced apoptosis of the cells by up to 50% (Liang et al., 2006). 
Eells et al., (2003) further showed that brief exposures of NIR light at 670 nm can 
reduce the toxicity of methanol derived formate in mitochondria. Research has also 
focused on Müller cells as these cells offer protection to photoreceptors in the 
retina. Albarracin and Valter, (2012) showed that treating albino rats with 670 nm 
light before exposing them to damaging light to induce retinal degeneration results 
in a reduction of light damage induced changes in Müller cells. 
1.5.2 Photoreceptors for red to near-IR light 
All photoreceptors discovered so far have a common feature: a protein with one or 
several chromophores covalently or non-covalently bound to the protein 
(Batschauer, 2003) and thus photoreceptors for red to near-IR light should display 
similar characteristics. Most of the current evidence points to cytochrome C oxidase 
as the primary photoacceptor for light in the far to near-IR range (Karu, 1999; Eells 
et al., 2004; Barolet, 2008; Gao and Xing, 2009). Cytochrome C oxidase is the terminal 
enzyme of the electron transport chain (ETC). Other photoacceptors that have been 
suggested including Complex II and IV of the ETC (Silveira et al., 2007), tyrosine 
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protein kinase receptor (Shefer et al., 2001) and the mobile electron transporters in 
ETC, cytochrome C, and Ubiquinone. 
1.5.3 Primary molecular mechanisms of PBM 
Mitochondria are important organelles in any cell to maintain its homeostasis 
through processes such as energy production, signal transduction, apoptosis and 
metabolism of amino acids, nucleotides, lipids and steroids. As a result, any 
biochemical changes in the mitochondria can have significant effect in cellular 
processes (Chinnery and Schon, 2003). 
The primary role of mitochondria in respiring cells are the aerobic catabolism of 
dietary intermediates such as fatty acids and amino acids into pyruvate (Duchen, 
2004; Burroughs and French, 2007). The pyruvate is eventually converted to carbon 
dioxide, water and ATP via the ETC. Cells such as neurons and cardiomyocytes, which 
are energetically active cells, require efficient ATP supply, and thus this can only be 
provided through mitochondrial oxidative phosphorylation via ETC (Duchen, 2004; 
Burroughs and French, 2007). 
It has been shown that mitochondria are sensitive to NIR light and it can absorb as 
much as 50% of the light through its chromophores, such as Cytochrome C oxidase 
(Beauvoit et al., 1995, Beauvoit et al., 1994).  
Cytochrome C oxidase is a large multi-component membrane protein (complex IV) 
of the ETC and it has been shown to have absorption bands in the red to near-IR 
spectrum (Huang et al., 2009). Its center consists of two heme moieties (heme a and 
heme a3), one zinc, one magnesium and two redox-active copper sites (CuA and 
CuB). All of these components are possible chromophores for red to near-IR light 
(Eells et al., 2004; Gao and Xing, 2009). Examples include increased electron transfer 
with 660-680 nm wavelength (Gordon and Surrey, 1960; Pastore et al., 2000) and 
upregulation of cytochrome oxidase activity in cultured neuronal cells (Wong-Riley 
et al., 2001). An Investigation by Karu et al. (1995) showed that the reduced form of 
CuA accepts light of 620nm wavelength, oxidized CuB accepts 680nm, reduced CuB 
accepts 760nm and oxidized CuA accepts 825nm. However, they also showed that 
cytochrome C is not the primary photoacceptor when it is in a fully oxidized or fully 
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reduced state (Karu et al., 1995; Karu and Kolyakov, 2005), therefore it is not clear 
which of the intermediates of cytochrome C oxidase is the primary photo acceptor 
(Gao and Xing, 2009). 
NO and N3 are reported to have considerable influence over cytochrome c oxidase 
activity and thus they are regarded as important intra-mitochondrial signaling 
regulators. These two gas molecules competitively bind cytochrome c oxidase by 
dislodging oxygen and as a result inhibit respiration in stressed cell to some degree 
(Reviewed - Brookes et al., 2002, Karu, 2008, Karu et al., 2004). NIR at 670 nm has 
been shown to reverse this process of cytochrome c oxidase inhibition by NO 
(Trimmer et al., 2009, Zhang et al., 2009). 
Mitochondrial retrograde signaling process is the communication between the 
mitochondria and nucleus of a cell which affects several cellular activities (Karu, 
1999; Gao and Xing, 2009) and this process can be initiated by the changes in ATP 
production, pH and mitochondrial membrane potential (MMP) following PBM 
treatment (Passarella et al., 1984). Subsequently, mitochondrial retrograde signaling 
is thought to initiate several pathways such as Mitogen-activated protein kinase 
(MAPK) cascade, extracellular signal regulated kinase (ERK) signaling, 
phosphoinositide 3 kinase (PI3K) and ATP-related signaling following PBM treatment 
(Gao and Xing, 2009).  
Mitochondria also play an important role in calcium storage and release. For 
example, mitochondria accumulate Ca2+ to protect the cell when cytosolic Ca2+ levels 
rise to critical levels. Following PBM treatment in hepatocytes and mast cells, it has 
been reported that there is an increased intracellular Ca2+ level and three to eight-
fold increase in intramitochondrial Ca2+ levels (Reviewed - Butow and Avadhani, 
2004, Karu, 2008, Scheffler, 2001). If the increased level of Ca2+ is sustained in the 
mitochondria then this can have a direct impact on the Krebs cycle, mitochondrial 
membrane potential and indirectly on the ATP/ADP availability (Wan et al., 1989). 
Disruption of the mitochondrial membrane potential releases Ca2+ in the cytosol, 
thus increasing intracellular Ca2+ concentration, which then enhances the activity of 
nuclear factor KB (NF-KB), several kinases and other signaling pathways to ultimately 
activate several nuclear genes. Hence Ca2+ is thought to be one of the primary 
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effectors of the mitochondrial-retrograde signaling mechanisms (Butow and 
Avadhani, 2004, Karu, 2008, Nicholls and Budd, 2000). 
Absorption of NIR light by mitochondria increases its membrane potential, ATP 
production and reactive oxygen species (ROS) production; all resulting in induction 
of signaling pathways and increase in energy availability (Reviewed - Gao and Xing, 
2009) (figure 11). Some of the cellular processes modulated by ROS include nucleic 
acid production and protein synthesis. They have also been shown to have effects 
on transcription factors such as NF-kB, AP-1, Ref-1, CREB and p53 (Reviewed – 
Hamblin and Demidova, 2006, Huang et al., 2009). 
 
Figure 11: Cellular signaling mechanisms of PBM. Schematic diagram showing NIR light 
absorption by mitochondria, which results in increased ATP production by the mitochondria, 
and also reactive oxygen species (ROS) and other signaling molecules like nitric oxide (NO). 
Increased ATP and ROS production can lead to transcriptional changes in the cell through 
activation of transcription factors like NF- ƙB and AP1 (figure adapted from Chung et al., 
2012 using Biorender.com). 
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1.5.4 Secondary signalling 
In other studies, NIR light has been shown to affect the expression of a range of genes 
critical to cellular functions, such as trafficking and degradation driving proteins, DNA 
repair proteins, antioxidant enzymes, molecular chaperones and proteins that are 
essential for cell growth and maintenance (Desmet et al., 2006). In a similar study, a 
cDNA microarray analysis of gene expression profile in human fibroblast cells after 
red light treatment showed increased expression of proteins that comprise the 
mitochondrial respiratory chain and anti-oxidant genes and a downregulation of 
genes that are involved in apoptosis and stress response.  
1.5.5 Importance of the 1068 nm wavelength 
Most of the work published for PBM has primarily focused on the 600nm-900nm 
wavelength. One of the major components of light penetration in tissues is its 
transmission through water, and narrow IR wavelength of 1068 nm is an optimum 
wavelength for transmission through water (Dougal and Kelly, 2001). Previous work 
with this wavelength has already shown its therapeutic potential such as improving 
the healing time of Herpes labialis (Dougal and Kelly, 2001), protecting against UVA 
toxicity in lymphocytes (Bradford et al., 2005) and improved acquisition of working 
memory in CD-1 mice (Michalikova et al., 2008). Bradford et al. (2005) have also 
shown that cell viability in human lymphocytes is the highest when treated with 1068 
nm wavelength compared to wavelengths of 660nm, 880nm, 950nm, 1267nm and 
untreated controls. Therefore, further experiments with IR light at a wavelength of 
1068 nm is essential to further establish the therapeutic potential of this wavelength.  
Near infrared (NIR) light (600-1500 nm) will be the focus of this study as it has been 
shown to have a range of biological effects and therapeutic benefits. NIR range of 
630-800 nm has high tissue penetrability as they have been shown to be able to 
penetrate up to 23 cm through the skin into muscle tissue. This range can also vary 
depending on the wavelength, tissue type and fluence; in addition, NIR absorption 
properties of tissues can vary depending on their constituents, such as water, fat and 
collagen (Hamblin and Demidova, 2006, Huang et al., 2009, Karu, 1999, Tsai et al., 
2001), along with the temperature and ion content and concentration (Tsai et al., 
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2001). One downside of this NIR range is that it is strongly absorbed by water, which 
limits its infiltration into deeper tissues. An alternative for this is NIR light at 1068 
nm, which requires less energy and intensity to enter biological matter, and can pass 
through water molecules (Bradford et al., 2005, Burroughs, 2010, Tsai et al., 2001). 
There have been numerous studies by our group that have implicated the 
importance of IR 1068 nm wavelength in various biological processes. Bradford et 
al., 2005, showed a cytoprotective effect of IR 1068 nm against UVA toxicity on 
human lymphocytes. Burroughs, 2010, found IR 1068 nm exposure provided  
concentration-dependent protection of rat primary cultures against glutamate-
induced excitotoxicity and most recently Duggett, 2013 established that IR 1068 nm 
can protect CAD neuronal cell line against Alzheimer’s disease-related insults such as 
hydrogen peroxide and β-amyloid (Grillo et al., 2013). 
 
1.6 Primary Aims and Hypotheses  
The aim of this project was to explore the possibility of a combination of H4 receptor 
ligands and photobiomodulation (1068 nm) as a synergistic 
modulation/cytoprotection strategy against oxidative stress/inflammation using an 
in vitro human retina glioculture model.  
 
The four primary hypotheses this project addressed were: 
• H3 and H4 receptors are differentially expressed in mouse and human 
retinal cells.  
• H4 receptor antagonists protect human Müller cells against oxidative 
stress-induced toxicity and inflammatory stress.  
• Functional H4 receptors exist on human histaminergic Müller cells.  
• PBM using NIR1068 nm protects human Müller cells against oxidative 
stress-induced toxicity and inflammatory stress. 
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Chapter 2 
Materials and Methods 
 
2.1 Frequently used medias, buffers and reagents 
Stacking gel buffer: 
0.5 M Tris-glycine, pH 6.8 containing 8 mM EDTA and 0.4% (w/v) SDS. 
Resolving gel buffer: 
50 mM Tris, 384 mM glycine, 1.8 mM EDTA, pH 8.8 and 0.1% (w/v) SDS. 
Stock acrylamide: 
40% (v/v) acrylamide and N,N’-methylenebisacrylamide. 
Electrode buffer: 
50 mM Tris, 384 mM glycine, 1.8 mM EDTA and 0.1% (w/v) SDS pH 8.8 
Sample buffer: 
30 mM sodium hydrogen phosphate, pH 7.0, 30% (v/v) glycerol, 0.05% (v/v) 
bromophenol blue and 7.5% (w/v) SDS. 
Pre-stained molecular weight markers: 
Pre-stained molecular weight marker stored in sample buffer 
Ammonium Peroxodisulphate (APS): 
1 mM in dH2O 
Dithiothreitol (DTT): 
200 mM in dH2O 
Transfer buffer: 
25 mM Tris, pH 8.4, 192 mM glycine and 20% (v/v) methanol. 
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Tris buffered saline: 
50 mM Tris-HCl, 0.9% NaCl pH 7.4. 
Tris/EDTA (TE) buffer: 
10 mM Tris, 1 mM EDTA, pH 8.0. 
Homogenisation buffer: 
50 mM Tris-HCl pH 7.4, containing 5 mM EDTA and 5 mM EGTA. 
H4 receptor binding buffer: 
50 mM Tris-HCl, pH 7.4 
Immunoblotting blocking buffer: 
5% marvel (w/v), 0.2% Tween 20 (v/v) and TBS pH 7.4 
Immunoblotting incubation buffer: 
2.5% marvel (w/v), TBS pH 7.4 
Immunoblotting wash buffer: 
2.5% (w/v), 0.2% (v/v) Tween 20, TBS pH 7.4 
ECL Developing solution A: 
1 ml 250 mM luminal, 0.44 ml 90 mM coumaric acid, 10 ml 1 M Tris-base pH8.5. 
Make up to 100 ml with dH2O 
ECL Developing solution B: 
64 μl 30% H2O2, 10 ml 1 M Tris-base, pH 8.5. Make up to 100 ml with dH2O 
Kodak developing solution: 
100 ml stock developer and 400 ml dH2O.  
Kodak fixative solution: 
125 ml stock fixer and 375 ml dH2O.  
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2.2 Lab techniques 
2.2.1 MTT Assay 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) uses 
mitochondrial dehydrogenase activity as a measure of cell viability. MTT solution was 
made up at a concentration of 25 mg/ml in sterile PBS and 80 µl of the MTT solution 
was added to each well and incubated for 2.5 hours at 37°C and at 5% CO2. After this 
time, all the solution along with the formazan crystals from the wells was transferred 
into Eppendorf tubes and centrifuged at 1000x g for 10 minutes. The supernatant 
was discarded and 250 µl of isopropanol added to each Eppendorf. After the 
Eppendorfs were vortexed, 100 µl of the solution from each Eppendorf was 
transferred to corresponding wells in a 96-welled (flat bottom) plate and the density 
of each well was measured spectrophotometrically at 595nm using a Multiskan 
Ascent Plate Reader, Version 2.6. Background readings (blank wells with cell medium 
and MTT) were subtracted from the average absorbance readings of the treated 
wells to get adjusted absorbance readings for cell viability of treated cells. 
2.2.3 Immunofluorescence 
In a fume hood, a sterile 13 mm glass coverslip was added to each well of a 6-well 
plate using sterile tweezers. Following steps for cell culture, the cells were 
transferred to the well-plate for final dilution of 1:2. The well-plates were placed in 
the incubator at 37°C, 5% CO2 overnight. After cells had reached around 70% 
confluency, media was removed from the wells and coverslips washed with 2 ml of 
PBS++ (1 mM CaCl2, 0.5 mM MgCl2 in PBS) for five minutes, twice. Cells were fixed in 
4% paraformaldehyde (10 ml paraformaldehyde in 30 ml PBS++) for 15 minutes and 
then washed twice, as stated previously. Free aldehyde groups were removed with 
50 mM NH4Cl for 15 minutes and then washed thrice as stated previously. Cells were 
then permeabilised using 0.1% (v/v) Triton X-100 in PBS++ for 10 minutes and washed 
a further time. Cells were then blocked using 0.2% BSA in PBS++ for 15 minutes, after 
which the primary antibody was diluted in 0.2% BSA according to the supplier’s 
recommendation, and cells were incubated with the primary antibody (0.5 µg/ml) 
for 90 minutes at room temperature. Cells without any primary antibodies were used 
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as a control. Cells were then washed three times with PBS++, each for 5 minutes and 
then incubated with the secondary antibody 1:500 anti-rabbit Alexafluorophore 488 
in 0.2% BSA for 25 minutes. After the incubation period, cells were washed twice 
with PBS++ for 5 minutes each and incubated again with 1:1000 anti-DAPI in 0.2% BSA 
for 10 minutes and coverslips were cleaned by dipping in dH2O after the incubation 
period. The coverslips were mounted on microscope slides using Mowiol 
(Calbiochem, UK). Cells were inspected using a Carl Zeiss Apotome microscope 
equipped with CO2 and temperature controls. Images were captured using 
Axiovision software. 
2.3 Light assays 
The apparatus for PBM treatments of cell cultures consists of LED arrays which emit 
infra-red light at 1068 nm. The LED arrays are grouped together and held above the 
cell culture plate so that all the cells in the plate are irradiated. Two different power 
outputs of LED were used for experiments, 3 mW/sq cm and 10 mW/sq cm. The 
temperature of the LED lights was kept at room temperature by cooling fans 
attached to the apparatus to prevent thermal drift of the peak wavelength. This 
apparatus for PBM experiments was supplied by Virulite Distribution Limited, UK and 
was validated by Dr. Gordon Dougal (Virulite Distribution Ltd, UK). All the PBM assays 
was carried out in 24-well plates, with three of the columns used for treatment and 
the other three used as sham (figure 12) 
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Figure 12: NIR1068 nm light treatment apparatus. All PBM experiments were carried out in 
24 well plates, with first 3 columns used for light treatment and the last 3 columns covered 
in foil for sham treatment.   
2.4 Cell cultures 
2.4.1 CAD cell culture 
CAD (Cath.-a-differentiated) cells were grown at 37°C and at 5% CO2 in 75 cm2 tissue 
culture flasks (Sarstedt, Newton, NC) in Dulbecco's modified eagles' medium DMEM 
/ F-12 Media - GlutaMAX™-I (GIBCO, Grand Island, NY), supplemented with 10% fetal 
bovine serum (FBS; Sigma, St. Louis, MO). CAD cells can differentiate to form 
neuronal processes in serum free media. To induce this morphological 
differentiation, cells were switched to same medium without serum 
supplementation after 24h. 
Splitting the CAD cell line  
The cells were passaged every 2-3 days at around 80% confluency at a 1:4 dilution. 
Original medium from the T75 flask was removed. 10 ml of DMEM / F-12 Media - 
Page | 41 
 
GlutaMAX™-I with 10% FBS was added to the flask and the cells are detached from 
the bottom through several pipetting steps. 10 ml of the cell mixtures were 
transferred to a 15 ml sterile Falcon tube and centrifuged at 100x g for 5 minutes. 
The supernatant was removed and 5 ml complete medium was added to resuspend 
the pellet. The cells were divided 1:4 into 75 cm2 flasks, with 10 ml total medium in 
each flask. 
Cryopreservation and storage of the CAD Cell line 
Sub-confluent cultures (70-80%) were dislodged by gentle pipetting; transferred to 
15 ml falcon tube and centrifuged at 200x g for 5 minutes at 4 oC. The pellet was 
resuspended in DMEM ⁄ F-12 Media - GlutaMAX™-I supplemented with 10% FBS and 
10% DMSO. The cell suspension was immediately divided into cryovials with 1 ml 
volume in each and stored at –80 oC for 24 hours and then transferred to liquid 
nitrogen. 
Resuscitation of frozen CAD and Müller Cell Line 
A cryogenic vial of cells from liquid nitrogen storage was collected and then quickly 
transferred to a 37°C water bath. It is important to thaw rapidly to minimise any 
damage to the cell membranes. The vial was then wiped with a tissue soaked in 70% 
alcohol prior to opening. The whole content of the vial was pipetted into 15 ml sterile 
falcon tube. Pre-warmed medium was added to reach a total volume of 10 ml, the 
tube was then centrifuged at 100x g for 5 min. Supernatant was removed and the 
CAD cell pellet was resuspended in DMEM⁄F-12 Media - GlutaMAX™-I supplemented 
with 10% FBS. Müller cell pellet was resuspended in Dulbecco’s Modified Eagle 
Medium 1X with GlutaMAX, without sodium pyruvate, 4500 mg/L D-Glucose 
supplemented with 10% FBS. The resuspended cells were grown at 37°C and at 5% 
CO2 in 75 cm2 tissue culture flasks. 
2.4.2 Müller glial cell culture 
Müller (MIO-M1) cells were grown at 37°C and at 5% CO2 in 75 cm2 tissue culture 
flasks (Sarstedt, Newton, NC) in Dulbecco’s Modified Eagle Medium 1X with 
GlutaMAX, without sodium pyruvate, 4500 mg/L D-Glucose (Cat number 61965-026, 
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Invitrogen UK) supplemented with 10% fetal bovine serum (FBS; Sigma, St. Louis, 
MO). 
 
Splitting the Müller cell line 
The cells were passaged every 3-4 days at around 80% confluency at a 1:5 dilution. 
Original medium from the T75 flask was removed. 3 ml of TryplE (‘trypsin’) (TryplE 
TM Express Enzyme (1X), no phenol red. Cat number 12604013) was added per T75 
flask, ensuring all cells are covered by the enzyme. The flask was then incubated at 
37°C and at 5% CO2 for approx. 3 min, until cells are rounded and floating. 10 ml of 
complete medium was added to the flask and 10 ml of the cell mixtures were 
transferred to a 15 ml sterile Falcon tube and centrifuged at 100x g for 5 minutes. 
The supernatant was removed, and 1 ml complete medium was added to resuspend 
the pellet. The cells were divided 1:5 into 75 cm2 flasks, with 10 ml total medium in 
each flask. 
Cryopreservation and storage of the Müller Cell line 
Sub-confluent cultures (70-80%) were dislodged by adding 3 ml of TryplE per T75 
flask; incubated at 37°C and at 5% CO2 for approx. 3 min, until cells are rounded and 
floating. 10 ml of complete medium was added to the flask and 10 ml of the cell 
mixtures were transferred to a 15 ml sterile falcon tube and centrifuged at 200x g 
for 5 minutes at 4 oC. The pellet was resuspended in Dulbecco’s Modified Eagle 
Medium 1X with GlutaMAX, without sodium pyruvate, 4500 mg/L D-Glucose 
supplemented with 10% fetal bovine serum and 10% DMSO. The cell suspension was 
immediately divided into cryovials with 1 ml volume in each and stored at –80 oC for 
24 hours and then transferred to liquid nitrogen. 
2.4.3 Calcium Imaging 
Müller cells were grown in Ibidi 35 mm µ-dishes as mentioned in section 2.4.2 at 
1:6 dilution 24 hours prior to the start of the experiment.  
On the day of the imaging experiments, the growth media from µ-dishes was 
removed and the cells were washed once with 1 ml of physiological buffer (150 
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mM NaCl, 1 mM MgCl2, 10 mM HEPES, 2 mM CaCl2, 5 mM KCl). The cells were 
then incubated for 40 minutes in 1 ml of 1μM dye solution (Fluo-4 AM (Life 
Technologies, Invitrogen™) at 37°C and at 5% CO2 in the dark. After the incubation 
period, the cells were washed once again gently with the physiological buffer in the 
dark and then kept in the physiological buffer and submitted immediately to the 
imaging experiments.  
For imaging, the µ-dish was placed in a chamber on the stage of the microscope at 
37°C and at 5% CO2. The field of cells was monitored by observing epifluorescence 
after excitation at 488 nm and images were acquired every 1 second, by 
programming the Zen 2™ (black edition) software to automatically do so. Cells 
were initially exposed to control (physiological buffer), followed by incubation with 
different concentration of drugs at 100 seconds interval. 
 
2.5 Statistical analysis 
All data were analysed using Microsoft Excel 2007 and GraphPad Prism version 8, 
GraphPad Software Inc. All column data are displayed as mean ± standard error of 
the mean (SEM). For comparing sham and IR1068 conditions, data were subjected 
to an unpaired two-tailed Student’s T-test and the other data were subjected to one-
way ANOVA analysis of variance, with a Bonferroni post-hoc test. 
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Chapter 3 
Histamine Receptors H4 in mouse and human retinal 
Müller cells 
 
3.1 Objectives 
The aim of this chapter was to determine the presence of H4 receptor in Müller cells 
under different culture conditions. Another aim was to also probe for the presence 
of histamine decarboxylase, HDC, in the Müller cells. The next aim was to perform a 
series of pharmacological experiments to determine the functional expression of H4 
receptors in Müller cells and test any therapeutic potential of the receptor. 
3.2 Introduction 
There is an increased histaminergic tone associated with diabetes, and emerging 
evidence also points to a role of histamine in the BRB breakdown that is associated 
with the pathogenesis of diabetic retinopathy (Leal et.al, 2005). This role of 
histamine in diabetic retinopathy is still not deeply investigated given the 
neurodegenerative nature of the disease and its effect on other components of the 
retina such as glial cells and neurons are considered. Also, since a lot of the 
investigations on the role of histamine in diabetes were before the discovery of the 
newest histamine receptors H3 and H4 (Panula et. al, 2015), there is lot of potential 
for new insights into the role of these receptors in diabetes and opportunity to 
develop new drugs and therapies.  
Histamine H4 receptor is a member of the GPCR superfamily like the other histamine 
receptors (Alexander et al., 2013), and it has a distinct pharmacological profile 
compared to the other receptors (De Esch et al., 2005). Recent evidence in the 
literature has implicated an important role of H4 receptor in vascular permeability as 
it has been shown to be expressed in rat brain endothelial cells. Based on this, we 
hypothesized an important role of H4 receptor in diabetic retinopathy. To test this, a 
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pilot immunological study was performed by our group previously on fixed mouse 
(C57 strain) retinal slices, which revealed a differential topological expression 
pattern. Results have shown that the histamine H3 and H4 receptors display a 
differential protein expression pattern. The H3 receptor labels all nuclear bodies in 
the photoreceptor layer (ONL) and some bipolar cells (INL) but little in the plexiform 
layers or ganglion cell layer (figures 13 and 14).  There are some processes labelled 
in the IPL, we think these are from histaminergic amacrine cells (figure 13). For the 
H4 receptor, these are mainly labelling the plexiform layers (IPL and OPL) (figures 13 
and 15). These might be in the Müller glial cells, and their endfeet are strongly 
labelled. As can be seen, there are faint stratifications in the IPL, and these are the 
ON and OFF sublamina divisions (figure 15). 
From these initial results observed in the mouse retina, where there was positive 
evidence for H4 receptor expression on the Müller cells, and the important role of 
these cells in diabetic retinopathy, we decided to focus on characterizing this 
receptor in-vitro in this chapter.  
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Figure 13: Immunohistochemistry of mouse (C57 strain) retinal slices. Cell were probed 
with DAPI (blue) and H3, H4 receptor specific antibodies (Abcam anti-HRH3 and anti-HRH4 
commercial antibodies) (red) showing differential H3 & H4 receptor topology in the mouse 
retina. 
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Figure 14: Immunohistochemistry of C57 strain retinal slices. Cells were probed with DAPI 
(blue), H3 receptor specific antibody (Abcam anti-HRH3 commercial antibody) (red), Thy1-
YFP (green) and RNA-binding protein with multiple splicing (RBPMS) (purple). H3 receptor is 
expressed on photoreceptors, some bipolar cells & Thy-1-ve/RBPMS +ve ganglion neurons 
 
 
Figure 15: Immunohistochemistry of C57 strain retinal slices. Cells were probed with DAPI 
(blue), H4 receptor specific antibody (Abcam anti-HRH4 commercial antibody) (red) and 
Glutamine Synthetase (GS) (green). H4 receptors are expressed on mouse plexiform layers & 
retinal Müller cells. 
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3.3 Methods 
 
3.3.1 Immunofluorescence for anatomical characterisation of histamine H4 
receptor and HDC 
IF on Müller cells was carried out as mentioned in section 2.2.3. For Müller cells 
exposed to high glucose environment, the cells were grown in Dulbecco’s Modified 
Eagle Medium 1X with GlutaMAX, without sodium pyruvate, 4500 mg/L D-Glucose 
(Cat number 61965-026, Invitrogen UK) supplemented with 10% fetal bovine serum 
(FBS; Sigma, St. Louis, MO). This experiment was repeated 4 times, and the images 
with the best resolution were selected. 
For low glucose environment, the cells were grown in Dulbecco's modified eagles' 
medium DMEM / F-12 Media - GlutaMAX™-I (GIBCO, Grand Island, NY), 
supplemented with 10% fetal bovine serum (FBS; Sigma, St. Louis, MO). This 
experiment was repeated 3 times, and the images with the best resolution were 
selected. 
3.3.2 Calcium2+ imaging of Müller cells stimulated with the H4 receptor 
agonists, VUF 8430 and ST-1006 
One of the downstream effects in the cell when H4 receptor is activated is the release 
of calcium from the intracellular storage vesicles through interaction with InsP3 
receptor. Thus, to determine the functional expression of H4 receptors in Müller 
cells, changes in the intracellular calcium concentration [Ca2+] of single Müller cells 
were measured by super resolution digital microscopy, using a Zeiss LSM 880 with 
Airyscan. Müller cells were grown in Ibidi 35 mm µ-dishes as mentioned in section 
2.4.2 at 1:6 dilution 24 hours prior to the start of the experiment.  
On the day of the imaging experiments, the growth media from µ-dishes was 
removed and the cells were washed once with 1 ml of physiological buffer (150 mM 
NaCl, 1 mM MgCl2, 10 mM HEPES, 2 mM CaCl2, 5 mM KCl). The cells were then 
incubated for 40 minutes in 1 ml of 1 μM dye solution (Fluo-4 AM (Life Technologies, 
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Invitrogen™) at 37°C and at 5% CO2 in the dark. After the incubation period, the cells 
were washed once again gently with the physiological buffer in the dark and then 
kept in the physiological buffer and submitted immediately to the imaging 
experiments.  
For imaging, the µ-dish was placed in a chamber on the stage of the microscope at 
37°C and at 5% CO2. The field of cells was monitored by observing epifluorescence 
after excitation at 488 nm and images were acquired every 1 second, by 
programming the Zen 2™ (black edition) software to automatically do so. Cells were 
initially exposed to control (physiological buffer), followed by incubation with 
different concentration of drugs at 100 seconds interval. 
All the test drugs were dissolved in the physiological buffer as stock solutions 10 
times more concentrated than the final desired concentration for the experiments. 
Any background reading was deducted from the cell fluorescence intensity, and the 
final fluorescence intensity was calculated by dividing the intensity of the cell with 
its area. The average fluorescence intensity of 5 cells were taken for graphical 
representation. 
3.3.3 Oxidative stress – dose determination in Müller cells 
Hydrogen peroxide (H2O2) is commonly used to elicit oxidative stress in cells. Usually, 
production of reactive oxygen species (ROS) such as H2O2, are a natural by-product 
of oxidative phosphorylation in the cell, and in low concentrations, they can act as 
signaling molecules for various cellular processes. However, high concentrations of 
H2O2 is detrimental to cells, where the ROS damages mitochondrial membrane 
potential, disrupting the ETC and thus ultimately results in the release of Cytochrome 
C and apoptosis (Beere, 2005, Tabner et al., 2005). Therefore, hydrogen peroxide 
was chosen to induce retinal damage to model this aspect of Diabetic Retinopathy. 
H2O2 induced insult with a series of different concentrations of H2O2 was carried out 
to determine the dose-dependent effects on Müller cell survival. A stock solution of 
H2O2 (2500 µM) in PBS was prepared and a series of different H2O2 concentrations 
were then prepared using Dulbecco’s Modified Eagle Medium 1X with GlutaMAX, 
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without sodium pyruvate, 4500 mg/L D-Glucose supplemented with 10% fetal 
bovine serum (FBS) to achieve final concentrations of 10 µM, 50 µM, 100 µM, 200 
µM, 250 µM, 300 µM, 400 µM and 500 µM. Sub-confluent cultures (70-80%) were 
dislodged as described in section 2.4.2 and transferred to a 15 ml falcon tube and 
centrifuged at 100x g for 5 minutes. The cell pellet was resuspended in Dulbecco’s 
Modified Eagle Medium 1X with GlutaMAX, without sodium pyruvate, 4500 mg/L D-
Glucose supplemented with 10% FBS. The cell suspension was then plated in 24-well 
plates and incubated at 37°C and at 5% CO2. The media was replaced after 24 hours 
with the different H2O2 concentrations prepared and grown in culture for 4-hour and 
24-hour time periods, after which an MTT assay was performed to determine cell 
viability (section 2.2.1). 
3.3.4 Glyoxal Treatment of Müller cells 
It is well known that diabetic retinopathy is a chronic, low-grade inflammatory 
disease, and several biochemical pathways have been implicated in this 
pathogenesis. One such pathway is the formation of AGEs, which irreversibly modify 
the chemical properties and functions of various key molecules (Wautier and 
Guillausseau, 2001). An intermediate of AGEs, glyoxal, has been shown in several 
studies of diabetes-associated retinal abnormalities to be an important and powerful 
inducer of cell apoptosis in the retina (Shen et. al, 2009; Kniep et. al, 2006). Glyoxal 
was also reported to cause inflammatory damage in human vascular endothelial cells 
(Yamawaki and Hara, 2008). More importantly, there is accumulating evidence that 
inflammatory factors contribute to the BRB breakdown associated with diabetic 
retinopathy (Joussen et. al, 2002; Carmo et. al, 2000; Funatsu et. al, 2001; Qaum et. 
al, 2001) and Müller cells have been demonstrated to be involved in the 
inflammatory process in-vitro (Walker and Steinle, 2007; Shelton et. al, 2007). A 
more recent study has demonstrated that glyoxal can induce inflammatory response 
in Müller cells in-vitro (Lei et. al, 2011). Therefore, in this study we have used glyoxal 
to induce inflammatory response in Müller cells and have checked whether it can be 
regulated by H4 receptor ligands under the condition of diabetic retinopathy.  
Sub-confluent cultures (70-80%) of Müller cells were dislodged as described in 
section 2.4.2 and transferred to a 15 ml falcon tube and centrifuged at 100x g for 5 
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minutes. The cell pellet was resuspended in Dulbecco’s Modified Eagle Medium 1X 
with GlutaMAX, without sodium pyruvate, 4500 mg/L D-Glucose supplemented with 
10% FBS. The cell suspension was then plated in 24-well plates and incubated at 37°C 
and at 5% CO2 until cells were 70-80% confluent in each well. Stock solutions (1 mM) 
of H4 receptor agonist VUF 8430 and antagonist JNJ 7777120 was freshly made up in 
dH2O. The H4 receptor ligand stock solutions were then added to the cells in the 24-
well plate (except control) to give a final concentration of 10 µM for both the agonist 
and the antagonist. The cells were then incubated for 1 hour at 37°C and at 5% CO2. 
After the one-hour incubation period, stock glyoxal solution (2 M) was added to the 
wells (except control) to give final glyoxal concentration of 2 mM and the cells were 
further incubated for 13 hours at 37°C and at 5% CO2 before extracting cell 
supernatant for TNF-alpha analysis and carrying out MTT assay (section 2.2.1) to 
determine the cytotoxic effects of glyoxal.  
Concentration of TNF-alpha was measured with Abcam’s TNF alpha Human in vitro 
ELISA (Enzyme-Linked Immunosorbent Assay) kit (ab 46087) according to the 
instructions of the kit. The values were compared with the standard curve of the 
cytokine and normalized to total protein concentrations.  
3.3.5 Neuroprotective assay using H4 receptor ligands in Müller cells 
Once an optimal dose of H2O2 was determined that elicited significant loss of cell 
viability, an assay was designed to check the neuroprotective effects of H4 receptor 
ligands in Müller cells.  
 Sub-confluent cultures (70-80%) of Müller cells were dislodged as described in 
section 2.4.2 and transferred to a 15 ml falcon tube and centrifuged at 100x g for 5 
minutes. The cell pellet was resuspended in Dulbecco’s Modified Eagle Medium 1X 
with GlutaMAX, without sodium pyruvate, 4500 mg/L D-Glucose supplemented with 
10% FBS. The cell suspension was then plated in 24-well plates and incubated at 37°C 
and at 5% CO2 until cells were 70-80% confluent in each well. Stock solutions (1 mM) 
of H4 receptor agonist VUF 8430 and antagonist JNJ 7777120 was freshly made up in 
dH2O. The H4 receptor ligand stock solutions were then added to the cells in the 24-
well plate (except control) to give a final concentration of 10 µM for both the agonist 
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and the antagonist and incubated for 1 hour at 37°C and at 5% CO2. After the one-
hour period, H2O2 was added to the corresponding wells from a stock solution of 
H2O2 (2500 µM) in PBS to give final concentration of 400 µM in the corresponding 
wells. The cells were kept in incubator for 4 hours, after which an MTT assay was 
performed to determine cell viability (section 2.2.1).  
3.4 Results 
Due to positive results seen for the presence of H4 receptor in-vivo as discussed 
previously, the focus was on characterizing the H4 receptor in-vitro using Müller cells 
to understand the important role of these cells in diabetic retinopathy 
The presence of H4 receptor and HDC was probed in Müller cells under different 
culture conditions using immunofluorescence. Once the presence of the receptor 
and enzyme was confirmed, a series of pharmacological experiments was performed 
to determine the functional expression of H4 receptors in Müller cells and test any 
therapeutic potential of the receptor. 
 
 
 
 
 
 
 
 
 
 
 
Page | 53 
 
3.4.1 IF shows the presence of H4 receptor in human Müller cells grown in 
different culture conditions. 
 
 
 
Figure 16: Immunofluorescence labelling for H4 receptor in human Müller cells grown in 
high glucose media. Cells were grown in High glucose media and probed with anti-H4R 
antibody (0.5 µg/ml) (In house anti-HRH4 commercial antibody (van Rijn, Chazot et al., 
2006) (green). Nuclei were stained with DAPI (blue). All the slides were examined at x20 (B) 
and x40 (C) magnification using Zeiss Apotome microscope and shows H4 receptor 
expression in the Müller cell processes (arrow heads) compared to control (A). Cells without 
any primary antibodies were used as a control. 
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Figure 17: Immunofluorescence labelling for H4 receptor in human Müller cells grown in 
low glucose media. Cells were grown in low glucose media and probed with anti-H4R 
antibody (0.5 µg/ml) (In house anti-HRH4 commercial antibody (van Rijn, Chazot et al., 
2006) (green). Nuclei were stained with DAPI (blue). All the slides were examined at x20 (E) 
and x40 (F) magnification using Zeiss Apotome microscope and shows H4 receptor 
expression in the Müller cell processes (arrow heads) compared to control (D). Cells without 
any primary antibodies were used as a control. 
 
Figure 16 and 17 shows Immunofluorescence labelling of human Müller cells. H4 
immunoreactivity was observed on the Müller cell processes (figure 16B-C and figure 
17E-F) compared to controls (figure 16A and 17D), and this expression seems to be 
higher – shown by higher immunoreactivity - in Müller cells when the cells were 
grown in high glucose media (figure 16B-C) compared to when they were grown in 
low glucose media (figure 17E-F).  
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3.4.2 IF shows the presence of HDC in in human Müller cells  
 
 
 
Figure 18: Immunofluorescence labelling for HDC expression in human Müller cells. Cells 
were grown in high glucose media and probed with HDC specific antibody (0.5 µg/ml) 
(Abcam anti-HDC commercial antibody) (green). Nuclei were stained with DAPI (blue). All 
the slides were examined at x20 (B) and x40 (C) magnification using Zeiss Apotome 
microscope, and shows HDC expression in the Müller cell processes (arrow heads) compared 
to control (A). Cells without any primary HDC antibodies were used as a control. 
 
Figure 18 shows Immunofluorescence labelling of human Müller cells. Histamine 
synthesis enzyme, HDC, immunoreactivity was observed on the Müller cell processes 
(figure 18B-C) compared to control (figure 18A).  
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3.4.3 Functional expression of histamine H4 receptor in Human Müller cells 
using selective H4 receptor agonists VUF 8430 and ST-1006 
 
 
Figure 19: Dose response in Müller cells for H4 receptor agonists VUF8430 and ST-1006. 
Changes in fluorescent intensity of Müller cells in response to control and 10 nM, 100 nM, 1 
µM, 10 µM and 100 µM concentrations of H4 receptor ligands. Following injection with 
control (PBS) for 100 seconds, the different concentrations of the drugs were injected at 100 
second intervals. The Ca2+ release induced fluorescent intensity of 5 different Müller cells 
from three independent experiments were measured and averaged for graphical 
representation. Experiments for both agonists were done separately and represented on the 
same scale. Arrows indicate the time points at which the different treatments were added 
to the cells.  
 
Figure 19 shows that following administration of the selective H4 receptor agonists 
VUF8430 and ST-1006, there was an increase in the fluorescence intensity observed 
in the cells. The increase in fluorescence was higher for ST-1006 treatment relative 
to VUF 8430 treatment and for both treatments, the max fluorescence was seen 
when the cells are treated with a dose concentration of 10 µM, which is consistent 
with similar experiments in the literature. The fluorescent intensity was used to 
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measure the H4 receptor activity through intracellular calcium mobilization from 
intracellular stores. This is consistent with an increase in the release of intracellular 
calcium from the cells upon H4 receptor activation.  
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3.4.4 Effects of concentration-dependent hydrogen peroxide insult (24 and 4 
hours) 
 
 
 
Figure 20: 24-hour and 4-hour dose-dependent effect on Müller cell survival using H2O2. 24 
(A) and 4 hours (B) insult of Müller cell cultures with varying hydrogen peroxide 
concentrations compared to cells treated with control (PBS). Cell viability was measured 
using MTT assay. Results are mean ± SD for one independent experiment performed in 
quadruplicate. * p <0.05 Vs control. 
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Figure 20 shows concentration dependent H2O2 insult in Müller cells of varying 
concentration and incubated for 24 hours (A) and 4 hours (B). This was to determine 
a concentration of H2O2 that would illicit a significant neurotoxic effect in Müller 
cells. With 24 hours incubation, only a concentration of 500 µM induced a significant 
loss of cell viability (67%) compared to control but this loss is too high for 
neuroprotective experiments. The protocol was then changed with higher starting 
concentrations of H2O2 and shorter incubation period of 4 hours. With this protocol, 
optimal loss of cell viability was achieved with 400 µM (50%) and 500 µM (60%). For 
neuroprotective experiments, H2O2 concentration of 400 µM and incubation period 
of 4 hours was selected.  
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3.4.5 Lack of protection with H4 ligands Vs oxidative stress 
 
 
 
Figure 21. Cell viability assay in Müller cells using H4 receptor antagonists VUF8430 and JNJ 
7777120 against oxidative insult. Müller cells were preconditioned with 10 µM of H4 
receptor antagonists VUF8430 (A) and JNJ 7777120 (B) for 1 hour before 4 hours oxidative 
insult with 400 µM H2O2. Control was treatment with PBS only for 1 hour. Cell viability was 
measured using MTT assay. Results are mean ± SD for two independent experiments 
performed in quadruplicates. ‘ns’ was compared to H2O2 treatment. 
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Figure 21 shows that there was no neuroprotection with H4 receptor agonist or 
antagonist when Müller cells are subjected to oxidative stress using H2O2. For 
treatment with VUF 8430 and JNJ 7777120, there was no significant difference in cell 
viability in comparison to 400 µM H2O2 treated cells. VUF 8430 and JNJ 7777120 
alone, also doesn’t seem to illicit a toxic effect in the Müller cells as there was no 
significant difference in cell viability when the cells are treated with agonist or 
antagonist only in comparison control cells. 
 
3.4.6 H4 receptor ligands worsen cell viability during inflammatory stress 
 
 
Figure 22: Cell viability assay in Müller cells using H4 receptor ligands against inflammatory 
stress. Müller cells were preconditioned with 10 µM of H4 receptor antagonist JNJ 7777120 
or agonist VUF8430 for 1 hour before 13 hours inflammatory insult with 2 mM glyoxal. 
Control was treatment with PBS only for 1 hour. Cell viability was measured using MTT assay. 
Results are mean ± SD for one independent experiment performed in quadruplicate. * p 
<0.05 Vs control or Glyoxal alone. 
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As seen from figure 22 that interestingly, when cells are preconditioned with H4 
receptor ligands for one hour and then stressed with 2 mM glyoxal for 13 hours, the 
cell viability decreases significantly compared to control or when cells are treated 
with glyoxal alone.  
Next, the supernatant of these cells was analysed for cytokine (TNF-alpha) 
expression levels (figure 23). This time, for cells preconditioned with VUF 8430 and 
then treated with glyoxal, TNF-alpha expression level increases significantly 
compared to control or when cells are treated with glyoxal only. Interestingly 
though, when the Müller cells are treated with the agonist alone, the cytokine 
expression level seems to be reduced compared to control or when cells are treated 
with glyoxal only.  
 
Figure 23: Effects of H4 receptor ligands on TNF-alpha expression when Müller cells are 
subjected to inflammatory stress. Müller cells were preconditioned with 10 µM of H4 
receptor antagonist JNJ 7777120 or agonist VUF8430 for 1 hour before 13 hours 
inflammatory insult with 2 mM glyoxal. Control was treatment with PBS only for 1 hour. 
Expression levels of the cytokine was measured using ELISA assay. Results are mean ± SD for 
one independent experiment performed in quadruplicate. * p <0.05 Vs control or Glyoxal 
alone. Expression levels of TNF-a shown in g/ml. 
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3.5 Discussion 
Initial immunological study performed by our group on fixed mouse (C57 strain) 
retinal slices showed positive evidence for H4 receptor expression in Müller cells in 
the plexiform layers. H3 receptor expression was only detected in the photoreceptor 
layers and in some bipolar cells but was absent in the plexiform layers. Thus, we 
decided to characterize the expression of H4 receptor in Müller cells in-vitro because 
of their importance in diabetic retinopathy. 
This chapter characterized the presence of Histamine H4 receptor in the Müller cells 
of the retina for the first time through Immunohistochemical and pharmacological 
studies. The chapter also explored the possibility of using H4 receptor ligands as a 
new therapeutic approach to treat diseases where the cells are under oxidative or 
inflammatory stress. 
3.5.1 Characterisation of Histamine H4 receptor in Müller cells 
Immunological studies using H4 receptor-specific antibody in Müller cells confirmed 
the presence of the receptor in the cells, specifically in the projections of the cells. 
This fits well with the observation in the mouse retina where H4 receptor labelling 
was seen in the end-feet of the Müller cells. When the cells were grown in high 
glucose media, this expression of the receptor appeared more prominent compared 
to when the cells were grown in low glucose media. This is consistent with several 
studies that has implicated the role of histamine in diabetic conditions through 
upregulation of histamine in different organs in diabetic patients and rats (Gill et al., 
1989; Fogel et al., 1990), and upregulation of the histamine H4 receptor (Pini et al., 
2018; Rosa et al., 2013) 
Histamine H4 receptor shares some homology with the H3 receptor (Leurs et al., 
2012), and H3 receptor has been widely accepted to act as both an auto- and hetero-
receptor to control the release of histamine and other neurotransmitters in the CNS; 
hence we further investigated this property in H4 receptor by investigating for the 
presence of HDC enzyme through immunofluorescence. HDC was also found to be 
present in the Müller cell processes; which suggests that there is nascent histamine 
pool in these glial cells. This observation further supports the studies in the retinas 
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of diabetic rats where there is an over expression of HDC and increased histamine 
synthesis (Hollis et al., 1992, Carroll et al., 1988; Gastinger et al., 2001).  
To further Illustrate the presence of H4 receptor, the immunostaining experiments 
need to be repeated with HDC knockout Müller Cell lines to demonstrate the 
specificity of the H4 receptor antibody for histamine cells in the retina. This 
experiment could then also be followed up with double staining of the Müller cells 
against H4 receptor and an antibody against HDC. 
On functional characterization of the H4 receptor in Müller cells, both the agonists, 
VUF 8430 and ST-1006, induced Ca2+ release from the intracellular calcium store in 
the cells. The agonist ST-1006 surprisingly induced a higher response in the cells as 
this H4-specific agonist is characterized as the most potent to date (Gschwandtner et 
al., 2013) but it is only a partial H4 receptor agonist. 
 
3.5.2 High tolerance for oxidative insult in Müller cells 
Müller cells seem to have a high tolerance for oxidative insults as illustrated by the 
high concentrations of H2O2 required to induce a significant loss of cell viability. This 
contrasts with other studies in the laboratory, when the same protocol was carried 
out in differentiated CAD (Cath.a differentiated) murine CNS catecholaminergic 
neuronal cell line (figure 24) where lower doses of H2O2 resulted in a large loss of cell 
viability. The ability of Müller cells to tolerate high levels of oxidative stress hints at 
intrinsic compensatory mechanisms in these cells to cope with oxidative stress as 
shown by Toft-Kehler et al., 2016, where they have shown that Müller cells with 
intact energy supply are only affected by oxidative stress at high concentrations. 
These results also emphasize the important protective and supportive role of Müller 
cells in the retina. 
To confirm the high tolerance of Müller cells to H2O2, the experiment needs to be 
repeated and quantified against a H2O2 sensitive cell line such as 293T-Cells. 
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Figure 24: 4-hour dose-dependent effect on CAD cell survival using H2O2. 4 hours insult of 
CAD cell cultures with hydrogen peroxide of concentrations of 100 µM, 120 µM, 140 µM, 
160 µM and 180 µM compared to cells treated with control (PBS). Cell viability was 
measured using MTT assay. Results are mean ± SD for one independent experiment 
performed in quadruplicate. * p <0.05 Vs control. 
 
3.5.3 Müller cell H4 receptor as a potential drug target against oxidative and 
inflammatory stress 
Because of the widespread expression of H4 receptor in different tissues types and 
its role in diabetes (Pini et al., 2015, Rosa et al., 2013) and vascular permeability 
(Karlstedt et al., 2013), the H4 receptor is a potential target for therapeutic 
interventions in diabetic retinopathy. On testing the H4 receptor agonist VUF 8430 
and antagonist JNJ 7777120 against oxidative stress, there was no significant 
difference in cell viability and the ligands were not effective in protecting against 
oxidative insults. When the same protocol was carried out against glyoxal-induced 
inflammatory insult, both the ligands seem to worsen the toxicity and on analysis of 
the cytokine TNF-alpha secretion in the treated cells, pretreatment of the cells with 
the agonist before inflammatory stress seems to increase the level of TNF-alpha 
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secretion significantly and when the cells are treated alone with the agonist, it has 
the opposite effect of reducing TNF-alpha level. This result suggests that H4 receptor 
agonist is effective in blocking production of basal level TNF-alpha in Müller cells as 
also demonstrated in a study by Gschwandtner et al.,2013, who showed that H4 
receptor agonist VUF 8430 reduces the cytokine IL-12 production in human 
monocytes and this production is only partially blocked by the antagonist JNJ 
7777120. There is evidence in the literature where JNJ 7777120 acts as a partial H4 
receptor agonist in some species (Wifling et al., 2015) and this might explain the 
partial blockage of IL-12 production by JNJ7777120 observed by Gschwandtner et 
al.,2013 in human monocytes. But the observation that treatment of Müller cells 
with VUF8430 or JNJ777120 worsens inflammatory stress-induced cell viability hints 
that during inflammatory stress, activation of the H4 receptor somehow worsens the 
toxicity induced by glyoxal. It will be interesting to use a neutral antagonist in the 
same experiment to compare to the effects of JNJ7777120 and determine whether 
JNJ7777120 was acting as a partial agonist in these experiments. A good candidate 
for another antagonist to use would be VUF-10214 or VUF-10148, which both have 
good H4 receptor potency and have also demonstrated anti-inflammatory properties 
in rat model of carrageenan-induced paw edema (Smits et al., 2008); therefore, if 
JNJ7777120 was substituted for a specific neutral antagonist in this experiment, then 
we might see inhibition of the negative effects associated with inflammation. 
3.5.4 Chapter Supplement and Support 
The histamine H4 receptor is the most recently identified histamine receptor 
(Nakamura et al., 2000; Oda et al., 2000) and it is particularly expressed in the tissues 
of the haematopoetic system. It was thought that H4 receptor is mainly involved in 
inflammatory diseases (Engelhardt et al., 2009; Gutzmer et al., 2011), but newer 
studies suggest that the receptor is also involved in other diseases such as 
neuropathic pain, cancer, vestibular disorders and type 2 diabetes (Gutzmer et al., 
2011; Kiss and Keseru, 2012). Because of this widespread role of the H4 receptor, its 
function needs to be thoroughly characterized for therapeutic interventions.  
The results from this chapter supplements and supports the initial characterization 
and distribution of the H4 receptor in the murine retina by our group. Further 
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pharmacological characterization of the receptor compliments other similar studies 
in the literature such as the intrinsic compensatory mechanisms in Müller cells to 
cope with high levels of oxidative stress (Toft-Kehler et al., 2016) and the ability of 
the H4 receptor agonist VUF8430 to block the cytokine IL-12 production in Müller 
cells (Gschwandtner et al.,2013). 
This chapter provided an anatomical and functional basis for H4 receptor in Müller 
cells and diabetic retinopathy. The next chapter will investigate whether an 
alternative method, PBM, rather than synthetic drug approach, with a specific 
wavelength, previously shown to be neuroprotective and immunomodulatory, has a 
positive effect against oxidative and inflammatory stress in retinal Müller glial cells. 
This will explore whether this device-based approach has potential as a therapeutic 
intervention against diabetic retinopathy. 
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Chapter 4 
Photobiomodulation in Müller Cells Against Oxidative 
and Inflammatory Stress 
 
4.1 Objectives 
The aim of this chapter was to determine whether PBM at NIR wavelength 1068 nm 
has any therapeutic potential against diabetic retinopathy. This will be investigated 
using human Müller cells of the retina, and diabetic conditions will be mimicked 
using H2O2 as oxidative insult and glyoxal to induce inflammatory stress. Since this 
was a novel procedure, different protocols were explored to determine optimal 
conditions for PBM treatment of Müller cells. 
4.2 Introduction  
The therapeutic benefits of light therapy have been known for many decades since 
its discovery by Endre Mester in 1967. Commonly PBM therapy is applied to wound 
healing, reduction in neurological pain, healing after peripheral nerve injury, heart 
attacks and stroke. But recently, PBM has been used as an innovative and non-
invasive therapeutic approach various sight-threatening retinal conditions such as 
age-related macular degeneration (AMD), diabetic retinopathy, retinopathy of 
prematurity (ROP) and methanol-induced retinal damage. There is shift away from 
traditional laser treatments for retinal conditions as devices containing LED arrays 
are available at only a fraction of the cost for lasers. 
It is widely acknowledged that mitochondria are the primary subcellular target of 
PBM and that cytochrome C oxidase in mitochondria serves as the primary 
photoacceptor. Stimulation of cytochrome C oxidase by PBM leads to an increase in 
energy production by mitochondria and also increases the metabolic rate and cell 
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proliferation (Hamblin and Demidova, 2006; Lovschall and Arenholt-Bindslev, 1998). 
Studies in the mouse retina have already shown that PBM leads to decrease in 
diabetes-induced inflammation on the retinal vessels (Tang et al., 2013). Since both 
mitochondrial health and the inflammatory state are affected by PBM, we 
hypothesized that PBM can treat diabetic retinopathy.  
4.3 Methods 
 
4.3.1 IR1068 nm apparatus and PBM assays 
The apparatus for PBM experiments was set up as discussed in section 2.3. In the 
PBM assays, H2O2 was used to illicit oxidative stress in the Müller cells and glyoxal 
was used to induce inflammatory stress as described in the previous chapter. 
Previous PBM work by our group (Bradford et al., 2005) involved testing a range of 
NIR treatment protocols on cell viability in human lymphocytes, and it was found 
that the protocol where cells were irradiated with NIR1068 nm using five 3 minute 
light exposures showed significantly higher cell viability compared to cells irradiated 
with other NIR wavelengths using the same protocol; hence the protocol for PBM 
assays in Müller  cells was devised based upon this previous work. Data were 
analysed using a one-way ANOVA followed by Bonferroni post-test. Data represent 
mean ± SEM. 
4.3.1.1  Müller light treatment pre H2O2 injection 
Sub-confluent cultures (70-80%) were dislodged as described in section 2.4.2 and 
transferred to a 15 ml falcon tube and centrifuged at 100x g for 5 minutes. The cell 
pellet was resuspended in Dulbecco’s Modified Eagle Medium 1X with GlutaMAX, 
without sodium pyruvate, 4500 mg/L D-Glucose supplemented with 10% FBS. The 
cell suspension was then plated in 24-well plates and incubated at 37°C and at 5% 
CO2 for 72 hours before use. 
Cells were exposed to five sets of either high power (10 mW/sq cm) or low power (3 
mW/sq cm) three-minute treatments of IR1068 nm or sham treatments, with 20 
minutes between each exposure. A stock solution of H2O2 (2500 µM) in PBS was 
prepared and different H2O2 concentrations were then prepared using Dulbecco’s 
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Modified Eagle Medium 1X with GlutaMAX, without sodium pyruvate, 4500 mg/L D-
Glucose supplemented with 10% fetal bovine serum (FBS) to achieve final 
concentrations of 300 µM and 400 µM. Media from the 24-well plate light-treated 
cells was replaced with the different H2O2 concentrations prepared and grown in 
culture for 4-hour period, after which an MTT assay was performed to determine cell 
viability (section 2.2.1). 
4.3.1.2  Müller light treatment post H2O2 injection 
A stock solution of H2O2 (2500 µM) in PBS was prepared and different H2O2 
concentrations were then prepared using Dulbecco’s Modified Eagle Medium 1X 
with GlutaMAX, without sodium pyruvate, 4500 mg/L D-Glucose supplemented with 
10% fetal bovine serum (FBS) to achieve final concentrations of 300 µM and 400 µM. 
Sub-confluent Müller  cell cultures (70-80%) were dislodged as described in section 
2.4.2 and transferred to a 15 ml falcon tube and centrifuged at 100x g for 5 minutes. 
The cell pellet was resuspended in Dulbecco’s Modified Eagle Medium 1X with 
GlutaMAX, without sodium pyruvate, 4500 mg/L D-Glucose supplemented with 10% 
FBS. The cell suspension was then plated in 24-well plates and incubated at 37°C and 
at 5% CO2. The media was replaced after 24 hours with the different H2O2 
concentrations prepared and grown in culture for 4-hour period.  
Cells were exposed to five sets of either high power or low power three-minute 
treatments of IR1068 nm or sham treatments, with 20 minutes between each 
exposure, after which an MTT assay was performed to determine cell viability 
(section 2.2.1). 
4.3.1.3  Müller light treatment pre and post H2O2 injection 
Sub-confluent cultures (70-80%) were dislodged as described in section 2.4.2 and 
transferred to a 15 ml falcon tube and centrifuged at 100x g for 5 minutes. The cell 
pellet was resuspended in Dulbecco’s Modified Eagle Medium 1X with GlutaMAX, 
without sodium pyruvate, 4500 mg/L D-Glucose supplemented with 10% FBS. The 
cell suspension was then plated in 24-well plates and incubated at 37°C and at 5% 
CO2 for 72 hours before use. 
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Cells were exposed to five sets of high power three-minute treatments of IR1068 nm 
or sham treatments, with 20 minutes between each exposure. A stock solution of 
H2O2 (2500 µM) in PBS was prepared and different H2O2 concentrations were then 
prepared using Dulbecco’s Modified Eagle Medium 1X with GlutaMAX, without 
sodium pyruvate, 4500 mg/L D-Glucose supplemented with 10% fetal bovine serum 
(FBS) to achieve final concentrations of 300 µM and 400 µM. Media from the 24-well 
plate light-treated cells was replaced with the different H2O2 concentrations 
prepared and grown in culture for 4-hour period. 
After the 4-hour period, the H2O2 media in the 24-well plate was replaced with 
Dulbecco’s Modified Eagle Medium 1X with GlutaMAX, without sodium pyruvate, 
4500 mg/L D-Glucose supplemented with 10% FBS.  
The cells were again exposed to five sets of high power three-minute treatments of 
IR1068 nm or sham treatments, with 20 minutes between each exposure, after 
which an MTT assay was performed to determine cell viability (section 2.2.1). 
4.3.1.4 Müller light treatment pre and post Glyoxal injection 
Sub-confluent cultures (70-80%) were dislodged as described in section 2.4.2 and 
transferred to a 15 ml falcon tube and centrifuged at 100x g for 5 minutes. The cell 
pellet was resuspended in Dulbecco’s Modified Eagle Medium 1X with GlutaMAX, 
without sodium pyruvate, 4500 mg/L D-Glucose supplemented with 10% FBS. The 
cell suspension was then plated in 24-well plates and incubated at 37°C and at 5% 
CO2 for 72 hours before use. 
Cells were exposed to five sets of high power three-minute treatments of IR1068 nm 
or sham treatments, with 20 minutes between each exposure. 
After the light treatment, stock glyoxal solution (2 M) was added to the wells (except 
control) to give final glyoxal concentration of 2 mM and the cells were further 
incubated for 13 hours at 37°C and at 5% CO2.  
The cells were again exposed to five sets of high power three-minute treatments of 
IR1068 nm or sham treatments, with 20 minutes between each exposure, after 
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which cell supernatant was extracted for TNF-alpha analysis and MTT assay was 
carried out (section 2.2.1) to determine the cytotoxic effects of glyoxal. 
 
4.4 Results  
Due to a previous study showing the beneficial effect of PBM against diabetes-
induced inflammation on the retinal vessels (Tang et al., 2013), the focus was to 
determine whether PBM at NIR wavelength 1068 nm has any therapeutic potential 
against diabetic retinopathy.  
The positive effects of PBM was investigated using human Müller cells of the retina, 
and diabetic conditions was mimicked using H2O2 as oxidative insult and glyoxal to 
induce inflammatory stress. Since there are no standard protocols for PBM 
experiments, different protocols were explored to determine optimal conditions for 
PBM treatment of Müller cells. 
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4.4.1 Low level light therapy does not protect Müller cells against 
oxidative stress 
 
 
Figure 25: Preconditioning of Müller cells with Low power NIR1068 nm treatment against 
oxidative insult. PBM treatment of Müller cells (3 mW/sq cm) was carried prior to 4 hours 
oxidative insult with 300 µM and 400 µM H2O2. Control was exposure to PBS with light (IR) 
and without light (sham). Cell viability was measured using MTT assay. Results are mean ± 
SD for one independent experiment performed in quadruplicates. ‘ns’ was compared to 
sham treatments. 
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Figure 26. Low power NIR1068 nm treatment of Müller cells post oxidative insult. Low 
power (3 mW/sq cm) NIR1068 nm treatment of Müller cells after 4 hours oxidative insult 
with 300 µM and 400 µM H2O2. Control was exposure to PBS with light (IR) and without light 
(sham). Cell viability was measured using MTT assay. Results are mean ± SD for one 
independent experiment performed in quadruplicates. ‘ns’ was compared to sham 
treatments. 
 
When Müller cells were preconditioned with low powered NIR1068 nm treatment 
before stressing them with two different concentrations of H2O2, there was no 
significant difference in cell viability compared to the cells which were treated with 
H2O2 but not exposed to any light treatment (figure 25). Thus, the next step was to 
alter the protocol and see if there is any increase in cell viability when the cells 
undergo PBM after exposure to H2O2. Again, figure 26 shows that low powered 
NIR1068 nm treatment of the cells post oxidative stress does not have any protective 
effect as there was no significant difference between the treatments and the sham 
experiment.  
Since low level NIR1068 nm treatment did not protect Müller cells against oxidative 
stress, the next step was to test the PBM apparatus with higher energy output. 
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4.4.2 High level light therapy has modest protection in Müller cells 
against oxidative stress 
 
Figure 27: High power NIR1068 nm treatment of Müller cells post oxidative insult. High 
power (10 mW/sq cm) NIR1068 nm treatment of Müller cells after 4 hours oxidative insult 
with 300 µM and 400 µM H2O2. Control was exposure to PBS with light (IR) and without light 
(sham). Cell viability was measured using MTT assay. Results are mean ± SD for one 
independent experiment performed in quadruplicates. * p <0.05 Vs 300 µM sham. ‘ns’ was 
compared to 400 µM sham 
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Figure 28: Preconditioning of Müller cells with high power NIR1068 nm treatment against 
oxidative insult. High power (10 mW/sq cm) NIR1068 nm treatment of Müller cells before 
4 hours oxidative insult with 300 µM and 400 µM H2O2. Control was exposure to PBS with 
light (IR) and without light (sham). Cell viability was measured using MTT assay. Results are 
mean ± SD for one independent experiment performed in quadruplicates. * p <0.05 Vs 400 
µM sham. ‘ns’ was compared to 300 µM sham. 
 
 
When the same protocol as the low powered NIR1068 nm light treatment were 
carried out with higher powered NIR 1068 nm light, both pre (figure 28) and post 
oxidative stress (figure 27) light treatment showed modest improvements in cell 
viability against oxidative stress.  
When the cells were preconditioned with light treatment before exposure to 
oxidative stress, the light treatment seems to improve cell viability when they were 
stressed with higher H2O2 concentration (400 µM) compared to cells stressed with 
300 µM H2O2, but the data variance for light treatment at 300 µM H2O2 treatment 
was too high compared the control and this needs further investigation.  
The result was opposite when the cells were treated with light post H2O2 exposure, 
as cell viability seems to improve for the lower H2O2 concentration compared to 
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control. Interestingly, for this method, there seems to be a significantly higher cell 
viability in the controls treated with light compared to controls under sham 
conditions (figure 27). 
 
4.4.3 Double treatment of Müller cells with high level light reduces 
oxidative stress  
 
 
Figure 29: High power NIR1068 nm treatment of Müller cells before and after oxidative 
insult. High power (10 mW/sq cm) NIR1068 nm treatment of Müller cells before and after 
24-hour oxidative stress with 300 µM and 400 µM H2O2. Control was exposure to PBS with 
light (IR) and without light (sham). Cell viability was measured using MTT assay. Results are 
mean ± SD for one independent experiment performed in quadruplicates. * p <0.01 Vs 300 
µM or 400 µM sham. 
 
On obtaining positive results with high powered NIR1068 nm treatment of Müller 
cells against oxidative stress, we decided to test another protocol where the cells 
would undergo light treatment twice, once before oxidative insult and once after. 
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This protocol has a much better protective effect and as can be seen from figure 29 
that there was significant improvement in cell viability (up to almost 50% increase) 
for both 300 µM and 400 µM concentration of H2O2 compared to sham treatments, 
to yield complete protection.  
Next, this same protocol was tested against inflammatory stress in Müller cells to 
see if there was any similar improvement in cell viability. 
4.4.4 Double treatment of Müller cells with high level light has no 
protective effect against inflammatory stress 
 
Figure 30: High power NIR1068 nm treatment of Müller cells before and after 
inflammatory insult. High power (10 mW/sq cm) NIR1068 nm treatment of Müller cells 
before and after 13-hour inflammatory stress with 2 mM glyoxal. Control was exposure to 
PBS with light (IR) and without light (sham). Results are mean ± SD for two independent 
experiment performed in quadruplicates. ‘ns’ was compared to glyoxal sham treatment. 
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Figure 31: TNF-alpha expression levels on high power NIR1068 nm treatment of Müller 
cells before and after Müller cells are subjected to inflammatory stress. High power (10 
mW/sq cm) NIR1068 nm treatment of Müller cells before and after 13-hour inflammatory 
stress with 2 mM glyoxal. Expression levels of the cytokine was measured using ELISA assay. 
Results are mean ± SD for two independent experiments performed in quadruplicates. * p 
<0.05 Vs Glyoxal dark. Expression levels of TNF-a shown in g/ml. 
 
When the double light exposure protocol was tested against inflammatory stress 
induced by glyoxal, there was no significant improvement in cell viability compared 
to the sham treatment (figure 30), although this treatment did not cause any 
significant cytotoxicity. The cell supernatant from this treatment was further 
analysed for TNF-alpha expression and interestingly it looks like there was complete 
protection from glyoxal-induced TNF-alpha secretion when the cells are subjected to 
the double light treatment protocol but the value was in the negative so it was not 
conclusive (figure 31). It will be of interest to repeat this and also check for the 
expression of other cytokines such as IL-1beta, IL-6 and VEGF using real-time PCR 
along with ELISA. 
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4.5 Discussion  
This chapter explored the therapeutic potential of using PBM at NIR wavelength 
1068 nm against both oxidative and inflammatory insults in Müller cells. According 
to the outcome of each experiment, the protocol was tweaked slightly for different 
experiments to obtain optimal conditions for protection against gliotoxicity caused 
by oxidative stress, and cytokine release induced in inflammatory stimulus both 
noted in retinal conditions such as diabetic retinopathy.  
4.5.1 Low powered NIR1068 nm treatment of Müller cells have no 
beneficial effect against oxidative stress 
When NIR1068 nm light apparatus with a power output of 3 mW/sq cm2 and energy 
density (energy per unit mass) of 0.6 J/cm2 was used to treat Müller cells against 
oxidative stress, there was no beneficial effect in cell viability compared to the sham 
treatments. This is not surprising as evidence suggests that effectiveness of PBM 
treatment varies on both the energy and power density used (Chung et al., 2012). 
This is termed as ‘biphasic dose response’, whereby levels above or below the 
optimum exposure conditions result in diminished biological effects and PBM seems 
to follow Arndt-Schulz law: if insufficient energy is applied, no effect will be 
observed, and if too much energy is supplied, ‘bio-inhibition’ occurs (Hamblin and 
Demidova, 2006, Huang et al., 2009). 
4.5.2 Double light treatment of Müller cells is more effective 
against oxidative stress compared to single treatments 
When both the power and energy density (energy per unit mass) of NIR1068 nm 
treatment was increased (10 mW/sq cm2 and 1.9 J/cm2 respectively), there was 
modest improvement in cell viability of Müller cells when they were preconditioned 
with the treatment before oxidative insult or when they were treated after oxidative 
insult. Surprisingly though, when the cells were preconditioned with the NIR1068 nm 
treatment, they seemed to have a protective effect only against the higher dose of 
H2O2. This observation seems to contradict the observation made by Duggett et al. 
(2013), who showed that NIR1068 nm preconditioning is not required for a profound 
Page | 81 
 
level of neuroprotection against H2O2 induced oxidative stress. Thus, these results 
need further investigation with a greater number of repeats.  
 
4.5.3 Double light treatment of Müller cells has no protective 
effect against inflammatory stress but seem to diminish 
cytokine release 
Since double light treatment of human Müller cells was successful in fully protecting 
the cells against oxidative stress, we had expected to see similar results for glyoxal 
induced release of TNF-alpha from human Müller cells despite no effect upon 
gliotoxicity. Indeed, when the cell supernatant was analysed post-glyoxal treatment, 
the double NIR treatment seemed to be successful in eliciting complete inhibition of 
cytokine (TNF-alpha) release, a common example of cytokines that are the major 
causes of inflammatory damage in cells. Although the levels of TNF-alpha released 
by glyoxal appear not to be sufficient to elicit gliotoxity, they may elicit neurotoxicity. 
It will be interesting to repeat this and check for the expression of other cytokines 
such as IL-1beta, IL-6 and VEGF using real-time PCR along with ELISA and perform 
retinal neuroglial co-cultures. The reduction in cytokine release seems to be 
consistent with the study performed in rats where the rats were treated with PBM 
following focal brain damage and the treatment reduced TNF-alpha and other 
cytokine levels in the brain, but interestingly the TNF-alpha level increased 
significantly in the blood (Moreira et al., 2009). 
4.6 Chapter Supplement and Support 
This chapter provided optimal PBM treatment conditions to protect human Müller 
glial cells against oxidative insults and inflammatory responses such as those seen in 
diabetic retinopathy, but the treatment against inflammatory stress needs further 
repetition as the cell viability remained consistent throughout all the treatments, 
which could indicate a non-cytotoxic effect of glyoxal on the cells in that particular 
experiment. The chapter also provided further evidence and support to existing 
theory that therapeutic effect of PBM is dependent on the energy density and 
treatment regime.  
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Cell proliferation following PBM treatment has been reported in several cell types; 
such as osteoblasts (Kreisler et al., 2003, Pires Oliveira et al., 2008, Ueda and Shimizu, 
2003), fibroblasts (Hawkins and Abrahamse, 2006, Taniguchi et al., 2009, Vinck et al., 
2003), muscle cells (Sommer et al., 2001, epithelial cells (Whelan et al., 2001) and 
neuronal cells (Grillo et al., 2013), and it will be interesting to further investigate 
whether the increased cell viability with PBM treatment was due to increased 
proliferation of the Müller  cells. This is unlikely as previously shown not to be the 
case for neurons (Duggett & Chazot, 2014). 
Since it’s already reported that there are increased ATP levels and mitochondrial 
electron transport activity following PBM (see introduction 1.6.3), further follow up 
experiments could measure ATP concentrations in sham and NIR1068 nm treated 
cell cultures to determine whether this was a factor in the increased cell viability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 83 
 
 
 
Chapter 5 
Overall Discussion and Future Work 
There were two main aims of this project: The first aim was to characterize the 
histamine H4 receptor in human Müller cells both anatomically and 
pharmacologically. The second aim was to determine where PBM at NIR wavelength 
1068 nm has any therapeutic potential against diabetic retinopathy. Overall, through 
these two main objectives, we wanted to understand whether targeting the H4 
receptor in Müller cells or PBM of the retina could either act as a potential 
therapeutic treatment on its own or combining the two treatment methods could 
illicit better results.  
Through a series of immunological and pharmacological studies, the following 
hypotheses have been addressed: 
1. Histamine H4 receptor is expressed in Human Müller glial cells 
Prior immunological study performed by our group on fixed mouse retinal slices 
showed positive evidence for H4 receptor expression in Müller cells in the plexiform 
layers. Thus, we decided to characterize the expression of H4 receptor in Müller cells 
in-vitro because of their importance in diabetic retinopathy. Immunological studies 
using a selective H4 receptor antibody confirmed the presence of the receptor in the 
projections of the Müller cells (consistent to the murine topology) when these cells 
were grown in both low and high glucose medium. Müller cells grown in high glucose 
medium seemed to show higher expression of the receptor. This does need further 
confirmation and quantification through western blot and PCR analysis. It wouldn’t 
be surprising if H4 receptor expression was indeed upregulated in high glucose 
environment as there is existing strong evidence for the upregulation of histamine 
and histamine H4 receptor during glycemia in other organs (Gill et al., 1989; Fogel et 
al., 1990; Pini et al., 2018; Rosa et al., 2013). Since some of the histamine receptors 
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like H3 have been shown to have both auto- and hetero-receptor activity, we further 
investigated whether H4 receptor has autocrine activity as well in Müller cells. For 
this we carried out IF again using HDC-specific antibody, and we found evidence of 
the enzyme expression in the processes of the Müller cells. An interesting follow up 
of these results would be to carry out immunohistochemical studies of Müller cells 
to check for direct evidence for the presence of histamine in these cells, and whether 
histamine release is controlled by the histamine H4 receptor, in order to better 
understand the potential cellular targets of histamine in the retina.  
On functional characterization of the H4 receptor through calcium imaging using 
agonists VUF8430 and ST-1006, both induced Ca2+ release from the intracellular 
calcium store in the cells but surprisingly ST-1006 induced a higher response even 
though VUF8430 is a full agonist for H4 receptor (Lim et al., 2009). Overall, when 
carrying out dose response assays in Müller cells with different concentrations of 
H2O2, these glial cells seem to have a high tolerance for oxidative stress compared to 
when the same experiment was carried out with neuronal CAD cells. This result 
further emphasized the important protective and supportive role of Müller cells in 
the retina. To further characterize the presence of H4 receptor in Müller cells, it’s 
important to use other methods to evaluate the receptor at the gene (RT-PCR) and 
protein (western/blot) levels. Further pharmacological analysis of the receptor 
should also be done to measure the levels of messenger molecules such as IP3 and 
cAMP on H4 receptor activation. In this study, only calcium imaging assay was 
deployed to characterize functional properties of the H4 receptor, but other tools 
such as electrophysiological techniques could be used to further confirm functional 
properties. 
2. H4 receptor ligands protect Müller cells against oxidative stress-induced 
toxicity and inflammatory stress 
The H4 receptor is a potential therapeutic target against diabetic retinopathy 
because of its role in diabetes (Pini et al., 2015, Rosa et al., 2013) and vascular 
permeability (Karlstedt et al., 2013). When both H4 receptor agonist VUF8430 and 
antagonist JNJ7777120 was checked for any protective effects against oxidative and 
inflammatory stress, there was no significant change in cell viability against oxidative 
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stress, but the ligands seem to make inflammatory stress induced toxicity worse as 
the cell viability decreases compared to control. On further analysis for the 
expression of the cytokine TNF-alpha in the supernatant from these cells, it was 
observed that VUF8430 in this treatment method increased the cytokine production 
compared to when cells were only stressed with glyoxal. This observation explains 
the decreased cell viability on treatment with the ligands. Further work needs to be 
done in terms of analyzing the production of other cytokines such as IL-1beta, IL-6 
and VEGF using real-time PCR along with ELISA.   
3. PBM at NIR1068 nm protects Müller cells against oxidative stress-induced 
toxicity 
PBM treatment of Müller cells against oxidative and inflammatory stress was carried 
out using two different power and energy densities. When lower powered PBM 
treatment was used, not surprisingly, there was no beneficial effect in cell viability 
compared to sham treatments, but when higher powered PBM treatment was used, 
there was modest protective effect in the cells. Next, we decided to perform double 
treatments of the Müller cells with high powered PBM, and this seemed to have a 
complete protective effective against both oxidative stress and an inflammatory 
response; the treatment seemed to completely block expression of the cytokine. 
Again, it will be interesting to also check for the expression of other cytokines such 
as IL-1beta, IL-6 and VEGF, and protective effect upon neurons in a co-culture.  
With PBM treatment, it is also important to understand the underlying mechanisms 
of light stimulation in the cells. There are already reports in the literature where PBM 
treatment causes increases in both cAMP (Karu, 1987) and ATP (Gao and Xing, 2009) 
levels. Bradford et al. (2005) also showed an increase in iNOS (inducible Nitric Oxide 
synthase) expression after NIR1072 treatment in human lymphocytes, and nitric 
oxide is known to act as a potent inhibitor of apoptosis. Therefore, it will be 
interesting to monitor the changes in protein expression levels during PBM 
treatment using RT-PCR. Also, it will be important to measure the basal levels of NO, 
ATP, Ca2+ and ROS before any PBM treatment as these components have been 
repeatedly reported to be increased following PBM treatment of cells; therefore, 
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depending on the basal levels of these components within a model, may determine 
the therapeutic output of the treatment. 
5.1 Future Work  
In this project, only two cellular stressors were used: glyoxal and H2O2. To have a 
broader understanding of the potential of the treatments used in this project as a 
potential therapeutic technique against diabetic retinopathy, it is important to test 
these protocols against other cellular stressors, including ER stressors.  
Currently, for PBM treatments, there is no standard protocol in the literature for 
treatments. Wavelengths, dose and treatment time vary depending on the scientist’s 
personal preference or experience; thus, it will be beneficial to further explore 
different protocols for treatment of Müller cells against various cellular stressors and 
develop a rigid and standard protocol that elicits the greatest benefit.  
Since out of the two treatment methods for diabetic retinopathy proposed in this 
study, PBM showed the greatest promise, it is important to further investigate the 
effects of IR1068 nm in an in-vivo system to check for any discrepancies and provide 
further insights into the mechanism of action through which NIR1068 nm treatment 
of Müller cells has been shown to be protective. 
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